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Head and neck cancers are the 11th most common malignancy worldwide1. 
Oral squamous cell carcinoma (OSCC) accounts for almost 95% of the malignant 
neoplasms which occur in the head and neck region.2 OSCC can occur in various 
parts of the oral cavity; the tongue is the most frequently involved site followed by 
the buccal mucosa, gingiva and the palatal regions. The tumor has a high mortality 
and a poor overall survival rate due to its invasiveness and metastatic capacity. 
Since many of the lesions are asymptomatic, there is a delay in their diagnosis. 
Majority of the OSCCs are usually preceded by asymptomatic conditions that are 
called Oral Potentially Malignant Disorders (OPMD) by World Health 
Organization (WHO). This term was adopted since it had been found that not all of 
the OPMDs progressed to malignancy.3 
Among the OPMDs, Oral submucous fibrosis (OSF) is a predominant 
condition of South East Asia, where it is associated with the habit of areca nut 
chewing. OSF has a high prevalence in the Indian sub-continent. It is usually seen 
in males in the age range of 20-40 years with the habit of areca nut chewing. The 
prevalence of OSF has increased over the years from 8.3% to 16.2%.4  
The main etiological agent for OSF is chewing of areca nut with or without 
tobacco products. The International Association of Research on Cancer (IARC) has 
classified areca nut as a Type – I (Substances that are known to be carcinogenic to 
human beings).5 Areca nut alkaloids such as arecoline, arecaidine, guacoline and 
guavacine cause disruption in the equilibrium of collagen homeostasis and 
upregulation of profibrotic cytokines such as Transforming growth factor- β (TGF- 
β). TGF-β belongs to a family of pro-fibrotic cytokine plays a role in the normal 
healing of wounds. 
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.The first case of malignant transformation in OSF was reported by JC 
Paymaster in 1956.6 The malignant transformation rate of OSF was reported to be 
around 7.6% over a 17 year period.7 In OSF cases with dysplasia, the malignant 
transformation rate was 4.84% and in those OSF cases which did not exhibit 
dysplasia the malignant transformation was 3.72%.8 The transformation of OSF to 
OSCC in another study was found to be 4.5% over a period of 14 years.9  
Advanced stages of OSF shows dysplastic features in the epithelium 
characterized by loss of cellular cohesion.10 The cellular cohesion maintains the 
continuity of the epithelium and keeps it intact. Oral epithelial dysplasias are more 
commonly associated with tobacco habits. They carry a high risk for malignant 
transformation. The loss of cellular cohesion is one of the architectural features of 
epithelial dysplasia, according to WHO criteria. Many studies have been carried out 
in cervical and mammary dysplasias and cell junctions. Cellular junctions comprise 
of tight junctions, adherens junctions and gap junctions. Gap junctions are 
transmembrane proteins that connect the cytoplasm of the neighboring epithelial 
cells by Gap junction intercellular communication channel (GJIC) through which 
various growth factors and secondary messengers are channeled.11 
 Connexins are specialized gap junction proteins expressed extensively 
throughout the tissues of the body. It is necessary for the normal functioning of 
epithelium and maintenance of cellular homeostasis.12 Connexin 43 (Cx43) is the 
most commonly expressed isoform. It is known that the loss of gap junction leads 
to the loss of cellular cohesion which promotes tumor progression and invasiveness. 
This could potentially play a part in the malignant transformation. Expression of 
connexin has been studied in fibrotic diseases such as liver cirrhosis, pulmonary 
fibrosis, systemic sclerosis and renal fibrosis. The altered expression of this Cx43 
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protein has been studied in various fibrotic diseases but the association of Cx43 
with OPMDs such as epithelial dysplasia and oral submucous fibrosis has not been 
reported in the literature. This study was aimed to study the expression of Cx43 
levels in OSF, epithelial dysplasia and in OSF cases where malignant 
transformation had occurred.  
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HYPOTHESIS:- 
There is no difference in the expression of Cx43 among OSF, Epithelial dysplasia 
and cases where OSF had undergone malignant transformation. 
AIM:- 
To evaluate the expression of Connexin 43 (Cx43), in formalin fixed paraffin 
embedded tissues of oral submucous fibrosis, epithelial dysplasia and OSF that had 
undergone malignant transformation to oral squamous cell carcinoma 
OBJECTIVES:- 
 To study the expression of Cx43in formalin fixed paraffin embedded  tissues of 
Oral submucous fibrosis by IHC 
 To study the expression of Cx43in formalin fixed paraffin embedded  tissues of 
epithelial dysplasia by IHC 
 To study the expression of Cx43 in in formalin fixed paraffin embedded tissues 
of OSF with OSCC by IHC. 
 To study the expression of Cx43 in formalin fixed paraffin embedded  normal 
epithelial tissue by IHC 
 To compare the expression of Cx43 among the study groups 
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 STUDY GROUPS:- 
 Group -   I:Normal oral mucosa obtained with the patients consent during 
third molar extraction(n=6) 
 Group - II: Clinically and histopathologically diagnosed cases of oral 
submucous fibrosis (OSF)(n=14) 
 Group- III: Clinically and histopathologically diagnosed cases of Epithelial 
Dysplasia (n=12) 
 Group-IV: Clinically and histopathologically diagnosed cases of OSCC with 
the history of OSF (n=7) 
 
SELECTION CRITERIA:- 
 Group I–Normal mucosa obtained during removal of impacted third molar in the 
outpatient department of Oral and Maxillofacial Surgery department.  
 Group II–The clinical criteria for selection of OSF patients were difficulty in 
opening the mouth, burning sensation of the mouth, palpable vertical fibrous 
bands in the oral mucosa. Histopathological criteria for OSF cases were epithelial 
atrophy, increased deposition of collagen in the oral mucosa,reduced vascularity, 
reduced number of inflammatory cells, and sub-epithelial hyalinization.OSF was 
histopathologically graded by criteria given by Pindborg and Sirsat13 
 Group III - Clinically and histopathologically confirmed cases of Epithelial 
dysplasia which were graded histologically as mild, moderate and severe 
 Group IV- Clinically and histopathologically confirmed cases of OSCC with a 
history of OSF. 
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INSTITUTIONAL REVIEW BOARD:- 
This study was approved by Institutional Review Board (IRB) of Ragas Dental 
College and Hospital, Chennai.(Annexure I) 
STUDY SETTING:- 
Department of Oral and Maxillofacial Pathology, Ragas Dental College and 
Hospital. 
METHODOLOGY:- 
 Archival tissue samples of oral submucous fibrosis, epithelial dysplasia and oral 
squamous cell carcinoma with history of OSF accessed from Department of Oral 
Pathology, Ragas Dental College and Hospital. 
 Demographic and pertinent details such as patient’s age, gender, past medical and 
dental history, history of drugs and trauma were obtained from records for OSF 
cases, OSCC arising in OSF cases and normal cases.  
 In group I, incisional biopsy were taken when patients were undergoing minor 
surgery for extraction of impacted teeth for normal oral mucosa after obtaining 
patient consent.  
 The tissue biopsied were rinsed and immediately transferred to 10% buffered 
formalin. After adequate fixation, tissues were embedded in paraffin. 
 From the paraffin embedded blocks, 5 micron thick sections were cut and used 
for routine hematoxylin and eosin (H&E) staining and immunohistochemical 
(IHC) staining. 
 Positive control for Cx43 was goat heart tissue sections. 
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Immunohistochemistry was performed by:- 
ANTIBODIES USED:- 
Primary antibody –Anti-Cx43 rabbit monoclonal antibody, Dilution: 1:100 CAT 
NO- 71-0700 (ThermoFisherScientificTM) 
Secondary antibody-Poly Excel-HRP Micro polymer, IHC Detection Kit, CAT 
NO- 36000 (ThermoFisherScientificTM) 
PROCEDURE 
The slides were dewaxed in xylene and rehydrated through grades of 
alcohol to water. The sections on the slides were flooded with Harris’s 
hematoxylin for 5 minutes. The slides were washed in running tap water for 5 
minutes. The slides were differentiated in 1% acid alcohol for 5 minutes. The 
slides were washed well in running tap water for 5 minutes. The tissue sections on 
the slides were then stained in eosin for 30 seconds. The slides were washed in 
running tap water for 1 minute. The slides were then dehydrated through alcohol, 
cleared, mounted and viewed under light microscope. 
IMMUNOHISTOCHEMICAL STAINING:- 
Armamentarium:- 
1) Microtome 
2) Autoclave 
3) Hot air oven 
4) Slide warmer 
5) Coplin jars 
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6) Measuring jar 
7) Weighing machine 
8) Poly L-Lysine coated slides 
9) Slide box 
10) Aluminium foil 
11) Micro-pipettes 
12) Toothed forceps 
13) Electronic timer 
14) Beakers 
15) Rectangular steel tray with glass rods 
16) Sterile gauze 
17) Cover slips 
18) Light microscope (LM) 
REAGENTS USED 
1) Poly-L-Lysine 
2) 1 N sodium hydroxide 
3) 1 N Hydrochloric acid 
4) 0.01 M sodium citrate buffer (pH 6.0) 
5) Phosphate buffered Saline (PBS) 
6) 3% Hydrogen peroxide 
7) Distilled water 
8) Hematoxylin 
9) Absolute alcohol (Isopropyl alcohol) 
10) Xylene 
Materials and Methods   
 
 
9 
  
PREPARATION OF PARAFFIN SECTIONS 
After the slides were dried, tissue sections of 5 micron thickness were 
made in a rotary manual microtome. The ribbons of tissue section were 
transferred onto the Poly-L-Lysine coated slides from the tissue float bath such 
that two tissue bits come on to each slide with a gap in between. One of the tissue 
sections towards the frosted end of the slide was labelled negative to which 
negative serum, the secondary and the chromogen were added and the tissue 
section away from the frosted side is the positive to which the primary antibody, 
secondary antibody and chromogen were added. 
IHC PROCEDURE 
The slides with tissue sections were treated with three changes of xylene 
to remove paraffin wax. They were put in descending grades of alcohol and then 
rehydrated with water. Circles were drawn using a diamond marker around the 
tissues, so that the antibodies added later on do not spread and are restricted to the 
circle. To expose target proteins, antigen retrieval was performed using 10mM 
sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, 
tissues were blocked for endogenous activity in 3% H2O2-methanol for 15 min at 
room temperature, washed with PBS, and then coated with Connexin 43 
monoclonal antibody (ThermoFisherScientificTM 138300) diluted in 3% PBS at a 
dilution of 1:100 overnight at 4°C. Tissues were washed in PBS and detection was 
performed using anstreptavidin-horseradish peroxidase (HRP)-conjugated 
secondary antibody followed by colorimetric detection using a 3,3-
diaminobenzidine tetrahydrochloride (DAB) kit. Tissues were counterstained with 
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hematoxylin and dehydrated with ethanol and xylene. The Slides were mounted 
with DPX and observed under light microscope. 
POSITIVE AND NEGATIVE CONTROL: 
Section of goat heart tissue that was positive for Cx43 was used as positive 
control. Negative control sections were processed by omitting primary antibody. 
IHC PROCEDURE: 
1. Poly-L Lysine coated slides with 2 paraffin embedded tissue placed in warming 
table 
2. Placed in xylene twice (5 minutes each) 
3. Placed in 100% isopropyl alchohol (5 minutes) 
4. Placed in 90% isopropyl alcohol (5 minutes) 
5. Placed in 70% isopropyl alcohol (5 minutes) 
6. Washed in distilled water (2 minutes each) 
7. Keep in 0.01 M sodium citrate buffer (pH 6.0) for antigen retrieval 
8. Placed in 3% hydrogen peroxide (7 minutes) 
9. Washed with PBS buffer (2-3 minutes) 
10. Primary antibody Cx43 (1:100) was added and incubated at 4°C overnight 
11. Washed in PBS buffer (2-3 minutes) 
12. Poly excel target binder reagent added and incubated (12 minutes) 
13. Washed in PBS buffer (2-3 minutes) 
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14. Poly excel HRP secondary antibody added and incubated (12 minutes) 
15. Washed slides in PBS buffer (2-3 minutes) 
16. DAB added and incubated (3 minutes) 
17. Washed in PBS thrice (2-3 minutes) 
18. Stained with Harris Hematoxylin (20 seconds) 
19. Washed in tap water 
20. Placed in 70% alcohol (1 minute) 
21. Placed in 100% alcohol (1 minute) 
22. Placed in xylene (1 dip) 
23. Slides to be mounted using DPX 
24. Slides to be observed under the LM and graded. 
EVALUATION OF H & E SECTION/S: 
 The H&E stained sections were thoroughly examined. Oral squamous cell 
carcinomas were graded as well differentiated, moderately differentiated and 
poorly differentiated. 
 Epithelial dysplasia were graded as mild, moderate and severe. 
 Oral submucous fibrosis was graded histologically by criteria given by Sirsat 
and Pindborg13. 
 Corresponding sections as examined by H & E were stained by IHC to detect 
Cx43 expression. 
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 The positive control was a section of goat heart tissue that was previously 
shown to be positive for Cx43. 
 Cx43 expression was evaluated as brown membranous staining in the 
epithelial cells. 
 The cells were then assessed for staining intensity. 
INTENSITY OF STAINING 
The staining intensity was analysed in the study groups. Each case was 
graded as (-) nil or absence of stain, (+) mild, (++) moderate and (+++) intense 
staining, based on the intensity of staining taken up by the tissue as observed by 
two blinded observers independently with respect to positive control. 
TISSUE LOCALIZATION: 
Epithelial cells that exhibited brown membranous staining were counted as 
positive for expression of Cx43. The sections were initially scanned at low power. 
For sections that showed heterogeneous staining, the predominant pattern was 
taken into account for scoring.  
CELLULAR LOCALIZATION OF STAIN: 
Cx43 expression was seen as brown membranous or cytoplasmic staining. 
The stained slides were screened, examined systematically for Cx43 expression in 
membrane, cytoplasm and walls of the epithelial cell. 
STATISTICAL TEST USED:The staining intensity between each groups was 
evaluated using Chi-squared test. For inter-observer reliability, kappa statistics was 
done (p<0.01). Data analysis to be done using SPSS software  version 21. 
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In 1952, Schwartz had five women from Kenya reported with stiffening 
and blanching of the oral mucosa, the palate andthe fauces, which was called 
"atrophiaidiopathica (tropica) mucosae oris". Joshi in 1953 described the 
condition as Oral Submucous Fibrosis (OSF).Later in 1966, OSF was defined by 
Pindborg and Sirsat as an“Insidious, chronic disease affecting any part of the oral 
cavity and sometimes pharynx. Although occasionally preceded by and/or 
associated with vesicle formation, it is always associated with a juxtaepithelial 
inflammatory reaction followed by fibro elastic change of the lamina propria, with 
epithelial atrophy leading to stiffness of oral mucosa and causing trismus and 
inability to eat”. 13 
 
EPIDEMIOLOGY:- 
OSF is prevalent in Southeast Asia and in the Indian Sub-continent. It is 
now reported worldwide due to migration of the population and the widespread 
use of areca nut due to commercialized preparations of areca nut. The prevalence 
of OSF in Southeast Asian countries like china was 1.0 - 3.03%14 and in Vietnam 
was 13% 15An epidemiological survey conducted in Taiwan by Shun Fa Yang et 
al that spanned over 17 years, found the prevalence of OSF increased from 8.3% 
in 1996 to 16.6% in 201316.In India, the prevalence has increased from 0.03% to 
6.42% over a period of 6 years 83and more than 5 million cases of OSF were 
reported from India 25 
 
In Southern India, the prevalence of OSF in Kerala was 2.01% and in 
Tamil Nadu it was 8%84. The gender predilection was0.2 to 2.3 % in males and 
1.2–4.57 % in females. Ranganathan et al., in their study had observed that OSF 
had frequently been associated with the habit of areca nut chewing with tobacco, 
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pan masala chewing and males had a higher prevalence19 The malignant 
transformation of OSF to oral squamous cell carcinoma (OSCC) was observed by 
JC Paymaster in 1956 6 It was designated as one among the Oral potentially 
malignant disorders (OPMD), since not all of the diagnosed OSF cases progressed 
to OSCC. Murti et al in 1986 reported a malignant transformation rate of 4.5% to 
7.6% two years later84. It has been suggested that longer follow up period may 
show a higher rate of malignant transformation. 
 
ETIOPATHOGENESIS:- 
OSF was strongly associated with the habit of areca nut chewing. The 
main etiological agent in areca nut is their alkaloids arecoline, a major areca nut 
alkaloid, whose active metabolite is arecoline N-oxide. It has been reported to 
have cytotoxic and genotoxic properties based on which the International 
Association of Research on Cancer (IARC) has classified areca nut as atype – I 
human environmental carcinogen20,5 The cytotoxicity and genotoxicity of areca 
nut alkaloids was studied in an experiment that involved cultured human buccal 
epithelial cells with areca nut alkaloids - arecaline, arecaidine, guavacine, 
quavcolineand N-nitrosamine compounds such as N-nitrosoguvacoline. They had 
caused DNA strandbreaks and decreased cell survival proving their cytotoxic and 
genotoxic property 21 
 
The areca nut/betel quidfibers and their alkaloids serve as a constant 
source of irritation to the oral mucosa resulting in micro-trauma at the site of 
placement. The micro-traumaallows the diffusion of the areca nut alkaloids into 
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the mucosa. This results in the production of reactive oxygen species (ROS) and 
inflammatory  
 
 
FIGURE 1: ROLE OF ARECA NUT IN INITIATION OF ORAL 
SUBMUCOUS FIBROSIS 
 
cytokines such as IL-6, TNF- α, TGF- β and IFN α.(Figure 1)Alkaloids and 
flavonoids of the areca nut are arecoline, arecaidine, guvacine and guvacoline. 
Arecoline is the highly active alkaloid that causes cholinergic and anti-muscarinic 
effects by binding to the GABA receptors in the brain, leading to psycho-
stimulativeeffects, Arecaidine has been known to stimulatecollagen production by 
buccal fibroblasts22. Areca nut flavonoidsincluding tannins and catechins promote 
a non-soluble, highly stable collagen structure by inhibiting collagenase activity. 
As OSF progresses, the type 3 collagen is completely replaced by type 1 collagen 
which are more resistant to degradation 23 
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Role of Copper in OSF  
 Copper content present in areca nut is involved in the pathogenesis of 
OSF. The enzyme lysyl oxidase is dependent on copper for its activation. It is 
responsible for the increased and highly stable cross-linking of the collagen by 
promoting hydroxylation of the collagen fibres. Trivedy et al 2001 conducted a 
study by culturing human fibroblasts with copper chloride and had found that 
copper had influenced the collagen production by the fibroblasts and the amount 
of collagen production was dose dependent. The same author had also studied the 
copper levels in the tissue of OSF, serum and urine of the individuals who had 
chewed areca nut for 5-10 min and it was found to be raised, concluding that 
copper was an initiator of OSF, which is responsible for the hydroxylation of the 
collagen fibres. 24 
 
Inflammatory cytokines and OSF: 
Pro-inflammatory cytokines are produced during inflammatory reactions 
by macrophages. They regulate fibroblast proliferation, migration and extra 
cellular matrix synthesis and reorganization. The balance between the cytokines 
plays a significant role in the initiation and progression of fibrotic disease. M. F. 
Haque et al., 2000 studied the production of cytokines such as IL-1β, IL-6, IL-8, 
TNF-α and IFN- γ from the peripheral blood mononuclear cells (PBMC) of OSF 
patients through flow cytometry and compared them with genetically-related 
relatives, who were control subjects. There was an increase in the levels of IL-1β, 
IL-6, IL-8 and TNF-α. These elevated levels of cytokines also had induced 
fibrosis in animal models 25. Areca nut extract also helps in the production of 
prostaglandins (PGE) and cyclooxygenase 2 (COX-2) in oral keratinocytes and 
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maintains the chronic inflammatory condition seen in OSF by activating the Nf-
κB pathway. 
 
Role of TGF- β in OSF 
Transforming growth factor - β (TGF- β), a pro-fibrotic growth factor, is 
involved in fibrosis and extracellular matrix remodeling.  There are various 
isoforms of TGF-β. TGF- β1 was expressed in epithelial, hematopoietic, and 
connective tissue cells, while TGF- β2 was expressed in epithelial, neuronal cells 
and TGF- β3 primarily in mesenchymal cells27. TGF-βcauses the deposition of 
extra cellular matrix (ECM) by increasing the collagen synthesis and decreases its 
degradation by activating tissue inhibitor of matrix metalloproteinase (TIMP).The 
immunohistochemical expression of TGF-β was observed in 70 tissue sections of 
OSF in a study done by VV Kamath et al., 2015. Both the isoforms of TGF- β1 
and TGF- β2 were found to be expressed in the tissues of OSF. When comparedto 
the control group, there was an increased expression of TGF- β1 in OSF tissues 
compared to TGF-β2.Connective Tissue Growth Factor (CTGF), pro-fibrotic 
mediator is associated with cell proliferation, adhesion, angiogenesis and tissue 
fibrosis in a pathologic state. Yi-Ting Deng et al., 2009 studied the 
immunohistochemical expression of CTGF in 20 tissue sections of OSF. They 
concluded a strong expression of CTGF staining in the endothelium and 
fibroblasts and concluded that it had a high fibrogenic activity than TGF- β and 
synergistically may induce a strong fibrotic response.39 
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Extracellular matrix remodelling and OSF 
Extracellular matrix (ECM) is composed of a network of collagens, 
proteoglycans/glycosaminoglycans, elastin, fibronectin, laminins, and several 
other glycoproteins. These glycoproteins bind with each other and provide a 
scaffold of support for the organ. Dynamic remodeling of the ECM is critical for 
normal development and wound healing. In the event of inflammation, when 
ECM remodeling gets disrupted or uncontrolled, it contributes to fibrotic diseases 
and malignancy.The extracellular matrix (ECM) remodeling with OSF 
progression was analyzed by Hiroko Utsunomiya et al 2005 who studied the 
expression of ECM proteins such as tenascin, perlecan, fibronectin, collagen type 
III in 40 tissue sections of OSF through immunohistochemistry and in-situ 
hybridization. They found that there wasan altered expression of ECM proteins in 
various stages of OSF, with the most advanced stages of OSF being characterized 
predominantly by type I collagen fibres, which are normally resistant to 
degradation.23 
 
Role of αvβ6 in OSF 
αvβ6, an integrin protein that is upregulated in inflammatory and 
pathologic conditions, plays a role in fibrosis and in malignancy. Elevated levels 
of αvβ6 activates TGF-β, which causes myofibroblast differentiation producing 
type-1 collagen fibers. KA Moutasim et al in 2011 tested the hypothesis if levels 
of αvβ6 was increased in OSF and αvβ6 expression was dependent on TGF-β for 
myofibroblast trans-differentiation. The level of αvβ6 expression was tested in 41 
tissue sections of OSF and 14 tissues of fibrous hyperplasia. Oral keratinocyte cell 
line that had expressed high levels of αvβ6 was developed along with normal cell 
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lines that were used as a control. The results showed that there was high staining 
of αvβ6 in tissue sections of OSF, as inhibition of TGF-β1 showed decreased 
myofibroblast transformation signifying that αvβ6 was dependent of TGF-β1. 
Oral keratinocytes induced with areca nut alkaloid also showed an upregulation of 
αvβ6 integrin 30 
 
Myofibroblasts and OSF 
Myofibroblasts are contractile fibroblasts that express α smooth muscle 
actin (αSMA). They are responsible for the tissue repair, cell motility, 
proliferation, differentiation, apoptosis, morphogenesis, tissue repair and are 
involved in fibrotic pathoses involving liver, lung, and kidney. Trans-
differentiation of the fibroblasts to the myofibroblasts is a crucial and early event 
in tumorigenesis, mediated by the growth factors and TGF-β expressed by the 
tumor cells. Myofibroblasts secrete numerous growth factors and inflammatory 
mediators that stimulate epithelial cell proliferation. Assessment of α-SMA was 
studied in 70 tissue samples of OSF of which 35 were diagnosed histologically as 
an early stage and 35 were advanced by PV Angadi et al in 2011 through 
immunohistochemistry. They found that there was a high expression of α-SMA in 
cases of advanced OSF when compared to controls which showed no 
expression.31 
 
CLINICAL FEATURES OF ORAL SUBMUCOUS FIBROSIS:- 
OSF is characterized by formation of palpable fibrotic bands of the oral 
mucosa resulting in reduced mouth opening. Stomatopyrosis with intolerance to 
consuming spicy food, blisters and ulcerations, dryness of the mouth followed by 
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vesicles, ulcers andmucosal pigmentation are commonly seen in early stages. As 
the condition advances, fibrosis progresses. The severity of the disease can be 
assessed by the severe limitation in mouth opening.In the advanced stages, there is 
restriction of tongue movement and shrinkage of the uvula. The faucial pillars 
become thick, short, and extremely hard. Leukoplakia is a common finding along 
with OSF, among patients with the habit of chewing tobacco products along with 
areca nut. 13 
 
HISTOPATHOLOGY OF ORAL SUBMUCOUS FIBROSIS: 
Histopathological features of oral submucous fibrosis vary according to 
the stages of the lesion. In early stages, it is characterized by atrophic oral 
epithelium. The connective tissue exhibits juxta epithelial hyalinization and 
thickened collagen bundles. Other findings include intercellular edema, 
constricted blood vessels and mild inflammatory cell infiltration. Sirsat and 
Pindborg gave histologic criteria that divides OSF into four stages such as early 
stage, very early stage, moderately advanced stage and advanced stage.13.In 
advanced stages, epithelial atrophy, dense collagen, hyalinization seen extending 
into the submucosal tissues were seen with lack of inflammatory cell infiltrate. In 
advanced cases of OSF, changes in epithelial dysplastic features may be observed 
and it may contribute to the malignant transformation. Jayasooriya et al studied 
the relationship thickness in OSF in 107 cases of histologically confirmed cases of 
OSF and stated that the features of epithelial dysplasia becomes more prominent 
as the condition of the OSF progresses, thereby increasing the possibility of 
malignant transformation. 
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OSF as an Oral Potentially malignant disorder:- 
OSF is an oral potentially malignant disorders (OPMD)33 The malignant 
transformation of OSF into oral squamous cell carcinoma (OSCC) was first 
reported by Paymaster in 1956. Wang YY et al., studied the prevalence rate of 
dysplasia that were associated with OSF. OSF that exhibited dysplastic features 
had a malignant transformation rate of 4.84% while those with no dysplastic 
changes showed a malignant transformation rate of 3.72% 4. In India, the highest 
rate of malignant transformation of OSF was 7.6%.  P Chaturvedi et al had 
suggested that OSCC arising in the background of OSF had a better prognosis 
than OSCC that were habit associated36. Various biomarkers have been studied for 
their suggested role in the malignant transformation of OSF such as the apoptotic 
markers studied by Ranganathan et al, angiogenic molecules by Chaudhary et al 
and reactive oxygen species.by Uikey et al in OSF. 
 
Role of Hypoxia in malignant transformation of OSF: 
Hypoxia was found to play a role in malignant transformation of OSF. It 
was suggested that reduced blood supply allowed the accumulation of carcinogens 
in epithelium.WM Tilakaratne, et al 2008 studied 48 cases of OSF and 17 cases 
of epithelial dysplasiathrough immunohistochemistry and RT-PCR. They found a 
positive expression of Hypoxia inducible factor- 1 α (HIF-1α) in the tissues of 
OSF and at the mRNA level in epithelial dysplasia. In another study carried out by 
Minal Chaudhary et al in 2015, HIF-1α expression was studied in 20 cases of 
OSF, OSCC and OSF associated with OSCC. The staining intensity and mean 
vascular density (MVD) were noted. They described the increase in the staining of 
HIF-1α from OSF to OSCC and the highest MVD was seen in the samples of 
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OSCC. They concluded that the increase in HIF-1α and MVD may play a role in 
the malignant transformation of OSF.35 
 
Senescence associated fibroblast and OSF: 
Senescent fibroblasts secrete growth factors, cytokines and degradative 
enzymes, which alter the tissue microenvironments and affect epithelial 
cells.Fibroblasts produce senescence-associated secretory phenotype (SASP) 
fibroblasts in response to constant DNA damage produced by ROS. A cell culture 
study by Hassona Y et al involving premalignant cells lines, has shown that SASP 
fibroblasts produce epithelial–mesenchyme transitional events by downregulating 
epithelial protein markers such as β-catenin, E-cadherin and cytokeratin and 
upregulating the expression of mesenchymal characteristics such as vimentin, N-
cadherin.SASPs are known to produce high levels of TGF-β and MMP-239 When 
associated with dysplasia, the senescent cells in OSF may contribute to the 
development and progression to OSCC in this disease. 
 
Cytokeratin Profiles: 
Cytokeratins (CK) which are the intermediate filaments of the epithelium 
form the cytoskeleton of the epithelial cells.Keratinocytes in oral epithelium are 
always matched in basic and acidic pairs (type I and type II) and are site 
specific.The expression of these cytokeratins remain stable through the malignant 
transformation and is a reliable marker for studying malignant differentiation 
40.The aberrant expression of cytokeratin has been demonstrated in various oral 
premalignant lesions 42 and in OSCC 41.The Cytokeratin expression in OSF was 
assessed through immunohistochemistry by Ranganathan K et al., 2006 in 50 
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tissue samples of OSF and it was concluded that there was an increase in the 
expression of cytokeratin 8 (CK8), Pancytokeratin (panCK) and high molecular 
weight cytokeratin (HMWCK) from normal controls to OSF and OSCC and 
concluded that these changes in cytokeratin maybe used as a surrogate marker for 
malignant transformation 42 
 
Genomic Instability in OSF and OSCC 
Genomic instability can be assessed through Loss of heterozygosity 
(LOH). LOH refers to the loss of genomic material that involves the normal copy 
of an allele. These regions contain oncogenes and tumour suppressor genes for 
normal function and maintenance. Most of the head and neck squamous cell 
carcinomas (HNSCC) involve the chromosomal regions such a 3p, 4q, 8p, 9q, 
11q, 13q and 17p (Uma Devi k Rao 2018) Event of LOH in OSF was studied by MT Teh 
et al 2007 through blood DNA samples of 15 OSF patients through Single 
nucleotide polymorphism (SNP) microarray mapping assay. They discovered 23 
hotspot loci in 47-53% of the OSF samples and involved the chromosomes 3p, 6q, 
9q, 12p, 13q and 20p.13q which was found to be lost in 90% of HNSCC cases, 
was also involved in the OSF. These LOH regions may play a role in the 
malignant transformation of OSF 43 
 
 
Epithelial Mesenchymal Transition 
 Epithelial Mesenchymal transition (EMT) describes the event in which a 
terminally differentiated epithelial cell acquires mesenchymal traits such as 
elongated, spindled shaped fibroblast like cells. This is also followed by a loss in 
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epithelial markers including E-cadherin, cytokeratin, zonula occludens-1 (ZO-1) 
and gain in mesenchymal markers such as vimentin, α- SMA and fibroblast-
specific protein-1 (FSP-1) which promoted motility of the cell.The inflammatory 
mediators produced in response to injury cause EMT, which could lead to 
fibrosis.The chronic inflammation seen in OSF promotes EMT events, involving 
the keratinocytes.The loss of E-cadherin along with β-catenin from the membrane 
might have led the cytoplasmic β-catenin to regulate thecanonical Wnt signaling 
pathway and the molecular determinants of epithelial polarity which have 
tumorigenesis enhancing impact through EMT44 
 
OPMDs – Epithelial dysplasia 
In India, 60–80% of patients present with advanced disease stages of 
OSCC due to delay in the diagnosis when compared to 40% in developed 
countries. These conditions are usually preceded by premalignant lesions that 
carry a high risk of malignant transformation. Among them, leukoplakia and OSF 
are predominant in the Indian sub-continent due to tobacco and betel-quid usage. 
 
Epithelial Dysplasia 
Among the OPMDs, leukoplakia is the most commonly encountered lesion 
carrying a high risk of malignant transformation. The lesion is frequently 
associated with the habit of tobacco smoking in the form of cigarettes and tobacco 
chewing. They clinically appear as a white patch involving the floor of the mouth, 
buccal mucosa and the tongue and it cannot be characterized as any other lesion. 
They have a prevalence rate of 2% with a malignant transformation rate of 8 to 
24%.   Based on the presence and extent of the dysplastic features, the malignant 
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risk 78 could be assessed, though not all of the dysplasia present could transform to 
malignancy. WHO grades epithelial dysplasia into three categories: mild, 
moderate and severe. Mild dysplasia is characterized by architectural and 
cytological changes that are confined to the lower one-third of the epithelium, 
while in moderate and severe dysplasia, the changes are seen extending into the 
middle third and upto the upper third of the epithelium, respectively.When the 
entire epithelial thickness is involved, it is labelled as carcinoma in-situ.  
Recently, in WHO 2017 classification of Oral dysplasia, loss of cellular cohesion 
has been accepted as an architectural feature in grading dysplasia3. The loss of 
intercellular communication is frequently involved in premalignant conditions and 
this intercellular communication is facilitated by gap junctions. Many studies have 
reported the loss of gap junction in dysplasia that had occurred elsewhere in the 
human body such as lung, cervix. 
Oral squamous cell carcinoma (OSCC) results from the chronic 
inflammation and multistep accumulation of genetic and epigenetic changes. 
OSCC has a high propensity for local invasion and cervical lymph node 
dissemination45.This results in a reduced overall survival rate. Therefore, earlier 
detection and treatment of OPMD such as epithelial dysplasia and OSF might 
inhibit and prevent the malignant transformation.Various panel of biomarkers 
have been studied in OSCC including expression of angiogenic markers, apoptotic 
markers, cell senescence markers, cytokeratin profiles, genetic 
susceptibility,tumor suppressor genes, oncogenes, cell proliferation markers and 
cell adhesion molecules to predict the malignant transformation in OSF (Figure 2). 
98.Chaturvedi and Sarode et al studied OSF cases that were associated with a 
history of OSCC and found that there was an increased overall survival rate in 
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patients with OSF-OSCC and they had a better rate of prognosis by a better tumor 
differentiation and decreased chances of nodal metastases. Loss of cellular 
communication occurs in severe dysplastic lesions and in tumor invasion and 
metastasis. The cellular communication is maintained by junctions of the 
epithelial cells. Among them Gap junctions contribute to a significant part in 
maintaining the cellular architecture.    
 
 
 
 
 
 
 
FIGURE 2. FLOWCHART SUMMARIZING FACTORS IMPLICATED IN 
THE MALIGNANT TRANSFORMATION OF OSF 
 
GAP JUNCTIONS AND CONNEXIN: 
Normal cell to cell communication and homeostasis is mediated through 
gap junctions which connects the cytoplasm of the neighboring cells to each 
other.The gap junctions are formed by transmembrane integral membrane proteins 
called Connexins (Cx).They are defined as ‘Clusters of a few to hundreds of 
tightly packed intercellular channels that, in the simplest assessment, function to 
allow small molecules to be directly exchanged between adjoining cells’. 11.The 
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connexins form gap junction intercellular communication channel (GJIC). These 
channels allows the exchange of metabolites, ions, growth factors and secondary 
messengers between the adjacent cells.It also maintains tissue homoeostasis, cell 
growth control and development48 
 
The connexins are synthesized in the rough endoplasmic reticulum (rER) 
of the golgi apparatus and oligomerizes similar to a membrane protein to form an 
individual connexon. These individual connexons are then transported and docked 
at the plasma membrane into a helical structure, where they are termed as 
connexin. These connexin molecules connect with the cytoplasm of the adjacent 
cell thereby allowing the passage of secondary messengers, ions, growth factors.49 
The connexin molecules have a narrow gap diameter of 2-4 nm. Multiple isoforms 
of connexins are expressed in different cell types throughout the body exhibiting a 
characteristic tissue and cellular distribution, signifying their functional 
differentiation. In humans, 21 isoforms of connexin have been identified50. 
Among them, connexin43 (Cx43) is found to be expressed in tissues of various 
organs. 
 
Morphology of Connexin:- 
Connexins are highly regulated integral trans-membrane proteins that 
consist of 2 extracellular loops, a cytoplasmic loop and cytoplasmic N- and C-
terminal (Figure 3). The C-terminal domain varies in its length and provide sites 
for protein-protein interaction 51.Connexins are named after their prefix- as Cx 
and by their molecular weight as kilodalton (kD) from their primary amino acid 
sequence. For example, connexin43 is 43 Kd52 
 Review of Literature  
  
28 
 
 
 
 
 
 
 
 
 
FIGURE 3: MORPHOLOGY OF CONNEXIN 
 
Connexin expression and gap junction communication are both regulated 
during the cell cycle. Connexin influences cell cycle by allowing the flow of 
growth factors and extracellular messenger that influence the expression of cell 
cycle regulatory proteins such as cyclin dependent kinases (CDK) and Cyclin 
inhibitory proteins (CIP)53. Reduced expression of connexins and Gap Junctional 
Intercellular Communication (GJIC) has been shown in many tumor types and 
have been recognized as tumor suppressors. Clinical studies show that deficient or 
abnormal connexins are frequently found in tumor tissues and cell lines, such as 
breast cancer, prostate cancer, lung cancers54 Cellular dissociation results in cell-
cell recognition impairment. Progressive loss of connexin has been observed to 
occur in advancing tumor stages that promote the invasiveness of the tumor. 
Aberrant GJIC levels were found to be due to lack of expression and cytoplasmic 
localization of the protein.  
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Cx43  
The connexin 43 gene, or gap junction associated protein 1(GJA1), is 
located at human chromosome 6q22-q23. Cx43 is the most widely expressed 
connexin isotype, found in tissues such as cardiomyocytes, keratinocytes, 
astrocytes, endothelial cells and smooth-muscle cells.55Cx43 has been extensively 
studied in tumors involving the breast, prostate, live r, lung and the brain as a 
surrogate marker for detecting early malignancy. Expression of connexin can be 
studied by analyzing the cellular localization and their expression level 56.In 
cancerous or chronic inflammatory conditions, phosphorylation and subcellular 
localization of Cx43 is considered to be an early event in carcinogenesis. 
 
The involvement of GJIC in malignancy was first demonstrated by 
Lowenstein and Kanno who had found a disruption in the electrical coupling 
between the cancerous liver cells due to a loss in GJIC 57.This decrease in 
connexin level has been suspected to be an early event in malignancy. Depending 
on the staging and the type of cancer, connexin can either act as a tumor 
suppressor or oncogene.58Based on this finding, connexin localization and both 
upregulation and downregulation is suspected to have a role in the prognostic 
outcome of the disease55 
 
ROLE OF CONNEXIN IN CARCINOMA:-  
The levels of Cx43 expression and their role in dysplastic cells was studied 
by TJ. King et al in 2000 through immunohistochemistry and cell culture in 10 
tissue samples of cervical dysplasia. They had found that Cx43 was significantly 
downregulated and to analyze the effect of this down regulation, they cultured 
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HeLa cells and studied the conduction of Cx43. It had revealed neoplastic 
progression of the dysplastic cells and loss of Cx43 influenced this process 59 
 
Immunohistochemical analysis and genetic mutational analysis of Cx43 
and Cx32 in 29 samples of colorectal carcinoma was carried out by MV Dubina et 
al in 2002. Their results suggested an aberrant cytoplasmic localization and 
connexin related disruption of GJIC during tumor invasion and metastasis. Cx43 
gene was found to be mutated in the cases of colonic carcinoma and wasfound to 
be responsible for the advanced stage of the disease progression 60 
 
A study by Kańczuga-Koda L et al., in 2003 analyzed the expression of 
Cx43 in 40 tissue samples of benign mammary dysplasias that consisted of 
papillomas, adenosis, cysts, intraductal and atypical hyperplasia and 25 tissue 
samples of normal mammary gland through immunohistochemistry. They had 
found that there was an altered expression (both of cytoplasmic and membranous 
expression) of Cx43 in the groups of cysts, adenosis, papillomas and decreased 
expression of Cx43 in the premalignant case of atypical ductal hyperplasia when 
compared to the normal mammary tissue where the Cx43 expression was seen 
intramembranous. The authors then concluded that loss of Cx43 was due to an 
early event in carcinogenesis.61 
Tatsuya Tanaka et al in 2006 assessed the prognostic influence of Cx43 
expression in 79 resected oesophageal cancer specimens with tumor grading and 
lymphatic invasion through immunohistochemistry. They found that 62 samples 
showed high positivity for Cx43 expression. They had also showed a shortened 
overall survival rate during post-operative follow up. This suggested a poor 
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prognosis when compared to the tissues that had a mild Cx43 expression. Based 
on this finding, they concluded that Cx43 could be used as an independent 
prognostic marker in esophageal carcinoma 62 
 
Can-Xia Xu et al in 2008 studied the expression of Cx43 and Cx32 in 
tissue sections of 33 cases of chronic superficial gastritis (CSG) with Heliobacter 
pylori (HP) infection and 88 cases of precancerous conditions and 70 cases of 
gastric cancer through immunohistochemistry. They had found that expression of 
both Cx32 and Cx43 were reduced in cases of gastric cancer associated with HP 
infections when compared to CSGs 63. 
 
Tang et al in 2011studied the expression of Cx43 and E-cadherin in 92 
samples of Gastric tumors and their associated lymph node metastases through 
immunohistochemistry. They found that there was decreased expression of Cx43 
and E-cadherin in gastric tumors, whereas the metastatic lymph node showed a 
high cytoplasmic expression of both Cx43 and E-cadherin. They had stated that 
reduction in the connexin channels might influence the invasiveness of the 
tumor64 
 
Immunohistochemical analysis of Cx43 in 348 tissue samples of urothelial 
carcinoma was studied by Poyet C et al., in 2015. They concluded that high 
expression of Cx43 staining was seen in the tissues as the stages of cancer 
progressed. This was a finding in contrast to the other findings found in the 
literature. The role of Connexin in tumours and in cancer progression varies due 
to cellular heterogeneity of the analysed tumours and the complex multilevel 
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process of tumorigenesis and progression. However, more reports suggest that 
Cx43 is overexpressed in some solid tumours and is involved in late metastatic 
steps. This could be demonstrated for breast cancer, melanoma and oral squamous 
cell carcinoma. 65 
 
Erdem and Çelik in 2017 studied the expression of Cx43 in 79 tissue 
samples of cervical intraepithelial neoplasia (CIL) that were graded between 1, 2 
and 3 through immunohistochemistry. Normal cervical epithelium was not 
included in the study as controls due to their lack of availability. Endocervical 
glands present in the dysplastic tissues served as an internal control. They found 
no expression of Cx43 among the dysplastic tissues but a mild expression was 
observed in the endocervical glands. They concluded that the lack of expression in 
the dysplastic tissues was due to loss of gap junction protein Cx43, secondary to 
the premalignant changes.66 
Hagemann et al in 2012 studied the expression of Cx43 in 37 tissue 
specimens of cervical dysplasia through immunohistochemistry and spectral 
imaging. They had observed the mild expression of Cx43 in clinically normal 
tissue adjacent to the dysplasia, followed by aberrant cytoplasmic expression in 
high grade squamous intraepithelial lesions (HSIL) and low staining of Cx43 in 
clinically normal mucosa. They concluded that the level of Cx43 expression can 
influence the stage of cervical intraepithelial neoplasia 67 
 
CONNEXIN 43 AND ORAL CANCER: 
Cx43 expression in tongue carcinogenesis was first carried out by Juan 
Xia et al in 2009 who had induced squamous cell carcinoma in rat tongue by 4-
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nitroquinoline-1-oxide. 48 tissue specimens with visible lesions on the rat tongue 
were taken and the staining of Cx43 was observed through 
immunohistochemistry. There was a lack of expression in the basal cell layer 
andan intense Cx43 expression in the cell membrane of spinous and the granular 
layer. The intensity of the Cx43 expression had gradually decreased in cases of 
oral cancer compared to the controls. They concluded that downregulation of 
Cx43 wasa crucial event in oral carcinogenesis 68 
 
Expression of Cx43 in the OSCC induced in rat tongue by 4-
nitroquinoline-1-oxide (4NQO) was studied by Feng Y et al in 2013 through 
immunohistochemistry in tissue samples of epithelial dysplasia (mild, moderate 
and severe) and OSCC of the rat tongue. There was positive expression of Cx43 in 
the membrane of epithelial cells in stratum spinosum, stratum granulosum and a 
lack of expression in the basal layer, cornified layer of the normal mucosa. In the 
dysplastic tissues, there was a progressive decrease in the expression of Cx43 
from cases of mild, moderate and severe dysplasia followed by a weak expression 
in OSCC. They concluded that a decrease in the expression of Cx43 is an early 
feature of oral carcinogenesis 69 
 
Feng Y et al in 2013 studied the expression of Cytokeratin 19 (CK 19) and 
Cx43 and their correlation through immunohistochemistry in tissue samples of 
epithelial dysplasia (mild, moderate and severe) and OSCC induced in rat tongue 
by 4-nitroquinoline-1-oxide(4NQO). They had found that there was positive 
expression of CK19, localized in the basal layer of normal lingual mucosa. 
Increased expression of CK19 was found in the suprabasal layers of mild, 
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moderate and severe dysplasia, In OSCC, there was a high intensity of CK19 
expression. Cx43 was expressed in the stratum spinosum and stratum granulosum 
in normal mucosa. In dysplasia and OSCC, their expression had been reduced 
significantly. The expression of CK19 and Cx43 had a negative correlation and 
thus was concluded that the combined expression of these markers might be used 
in the early diagnosis of OSCC 70 
Brockmeyer et al., (2014)studied thelocalization pattern of Cx26, Cx43 
and Cx45 in 35 tissue samples of OSCC along with normal oral mucosa and 
lymph node metastases through RT-PCR and immunohistochemistry. There was 
lack of Cx26 expression in normal oral mucosa but there was positive expression 
in the cytoplasm of neoplastic cells.The membrane expression had decreased with 
increasing keratinization seen in OSCC. This keratinization leads to a reduction in 
the cell membrane, resulting in sub-cellular localization of Cx43 following its 
subsequent degradation leading to an increase in the cytoplasmic expression in 
OSCC.71 
 
The studied was continued by Brockmeyer P et al in 2014 where the 
membranous expression of Cx43 and its prognostic value was assessed through 
immunohistochemistry. They had observed a high membranous Cx43 expression 
in samples of OSCC and lymph node metastasis which was associated with poor 
prognosis and reduced overall survival period. A mild membranous expression of 
Cx43 was also seen in clinically normal mucosa adjacent to the tumor. They 
concluded their study stating that high membranous expression of Cx43 was an 
independent prognostic marker of the tumor, which was associated with poor 
prognosis 72 
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An immunohistochemical study byLidia Puzzo et al 2016 analyzed the 
expression of Cx43 in 87 tissues of untreated resected specimens of laryngeal 
squamous cell carcinoma. They had found a mild expression of Cx43 in well 
differentiated and moderately differentiated carcinoma. There was no expression 
of Cx43 in poorly differentiated samples. The moderately differentiated 
carcinomas with lymph node metastasis showed aberrant Cx43 expression that 
was associated with decreased overall survival period during follow up and 
showed poor prognosis. They concluded that carcinomas which did not exhibit 
Cx43 expression had a better prognosis than a carcinoma having an aberrant Cx43 
expression that involves metastasis and poor prognosis73 
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SAMPLE CHARACTERISTICS:- 
The study population comprised of 39 cases from the archival specimens of 
department of oral and maxillofacial pathology. The study population was 
comprised of four groups. Group I (n = 6) was comprised of Normal oral mucosa 
obtained during the extraction of third molars. Group II (n = 14) comprised of 
Oral submucous fibrosis samples, Group III consisted of Epithelial dysplasia (n 
=12) that were associated with habits and Group IV comprised of OSCC 
associated with OSF (n = 7). All the tissue samples were analyzed for Cx43 
immunostaining 
 
Distribution of age among the study groups (Table I & Graph I):- 
The age among the study groups were divided into 3 categories: < 25 years, 25-
50 years and > 50 years. In group I, 1(16.7%) case was in the age group < 25 
years and 5(83.3%) the cases were between the age group 25-50 years. Group II 
had 7(50%) cases between the age 25-50 years of age and 7(50%) cases were in 
the age group >50 years. Group III had 6(50%) cases within 25-50 years and 
6(50%) of cases in the age group >50 years. Group IV had 2(28.6%) cases 
within 25-50 years and 5(71.4%) of cases > 50 years. The difference in age 
distribution between the groups was not significant (p=0.081). 
 
Distribution of gender among the study groups (Table II & Graph II):- 
In group I, 4(66.7%) cases were males and 2(33.3) % were females. In group II, 
10(71.4%) of cases were males and 4(28.6%) cases were females. While group 
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III had 11(91.7%) were males and 1(8.3%) female, group IV had 6(85.7%) was 
males and 1(14.3%) of females. The difference in gender distribution between 
the groups was not significant (p=0.490). 
 
Distribution of habits among the study groups (Table III & Graph III):- 
The habits among the study groups were divided into six categories based on 
their habit as those who chewed areca nut, those who chewed tobacco, those 
who chewed areca nut and tobacco, those who only smoked, those who smoked 
with tobacco and areca nut chewing and those without habits. In group I, all 
6(100%) cases had no habits. In group II, 9(64.3%) chewed areca nut, 5(35.7%) 
had the habit of chewing areca nut and tobacco. In group III, 7(58.3%) had the 
habit of chewing tobacco, 1(8.3%) had the habit of chewing areca nut and 
tobacco, while 4(33.3%) had the habit of smoking.  In group IV, 4(57.1%) had 
the habit of chewing tobacco and arecanut while 1(14.3%) had the habit of 
smoking and areca nut chewing and 2(28.6%) had the habit of smoking along 
with tobacco and areca nut chewing. The distribution of habits between the study 
groups was statistically significant (p=0.000). 
 
Distribution of site of the lesion among the study group (Table IV & Graph 
IV):- 
In group I, 3(50%) of the cases were from buccal mucosa and 3(50%) of cases 
were from the alveolar mucosa. In group II, all 14(100%) of the cases were from 
the buccal mucosa. In group III, all 12(100%) of the cases were from buccal 
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mucosa and in group IV, 3(42.9%) of the cases were from buccal mucosa, 
1(14.3%) from alveolar mucosa, 1(14.3%) from palate and 2(28.6%) cases from 
the lateral border of the tongue. The difference in distribution of the site of the 
lesion was statistically significant between the groups (p=0.001*). 
 
Distribution of Cx43 staining among the study groups (Table V & Graph 
V):- 
All the tissue sections were analyzed for immune-histochemical staining of 
Cx43. Among them, in group I, 5(83.3%) cases had Cx43 expression and 
1(16.7%) did not express Cx43. In group II, 13(92.9%) cases had expressed 
Cx43 staining while 1(7.1%) showed no expression. In group III, 8(66.7%) had 
Cx43 expression, while 4(33.3%) had no expression of Cx43.  In group IV, 
6(85.7%) had positive Cx43 expression, whereas 1(14.3%) had no 
expression.The difference in Cx43 expression between the groups was not 
significant (p=0.375). 
STAINING INTENSITY:- 
The Cx43 staining intensity was analyzed in the study groups and graded as (-) = 
Negative or absence of staining, (+) = Mild staining, (++) = Moderate staining, 
and (+++) = Intense staining. 
INTEROBSERVER VARIATION IN Cx43 STAINING INTENSITY:- 
The kappa value for inter observer variation is 0.8 
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Comparison of Cx43 staining of basal layer among the study group (Table 
VI& Graph VI):- 
In group I, all of the cases 6(100%) showed no Cx43 expression.  In group 2, 
10(64.3%) showed no expression of Cx43, 3(21.4%) had mild expression for 
Cx43 and 1(7.1%) had moderate staining for Cx43.  In group III and group IV, 
all 12(100%) and 7(100%) cases were negative for Cx43. (p=0.241). 
 
Comparison of Cx43 staining of suprabasal layer among the study group 
(Table VII& Graph VII):- 
In group I, 1(16.7%) case had no expression of Cx43 and 5(83.3%) cases 
had mild staining for Cx43.  In group II, 2(14.3%) were negative for Cx43, 
7(50%) case had mild expression for Cx43 and 5(35.7%) cases had moderate 
staining for Cx43.  In group 3, 5(41.7%) were negative for Cx43, 4(33.3%) had 
mild expression for Cx43 and 3(25%) cases had a moderate expression for Cx43. 
In group IV, 5(71.4%) cases were negative for Cx43, 1(14.3%) had mild staining 
for Cx43 and 1(14.3%) had intense expression for Cx43. The difference in Cx43 
staining intensity between the groups was statistically significant (p=0.033). 
 
Comparison of Cx43 staining in the connective tissue among the study 
groups (Table VIII& Graph VIII):- 
          In group I, 1(16.7%) case had no Cx43 expression, 4(66.7%) case had 
mild staining for Cx43 and 1(16.7%) case had moderate staining for Cx43 in the 
connective tissue.  In group II, 1(7.1%) case had no expression of Cx43, 
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5(35.7%) cases had mild staining for Cx43, 7(50%) cases had moderate staining 
for Cx43 and 1(7.1%) case had intense staining for Cx43 in the connective 
tissue.   In group III, 4(33.3%) cases were negative for Cx43 expression, 
5(41.7%) cases had mild expression for Cx43 and 3(25%) cases had a moderate 
expression for Cx43 in the connective tissue. In group IV, 5(71.4%) had mild 
staining for Cx43, 1(14.3%) case had moderate staining for Cx43 and 1(14.3%) 
case had intense staining for Cx43. The difference in staining intensity of Cx43 
in the connective tissue was not significant (p=0.279). 
 
Comparison of Cx43 staining of suprabasal cell layer among different 
grades of Oral Submucous Fibrosis (Table IX and Graph IX):- 
         Among the OSF group, in the very early stage, 1(25%) case had no 
expression and 3(75%) cases showed mild expression for Cx43.  In early stage, 
1(14.3%) case showed no expression, 3(42.9%) cases showed mild expression 
for Cx43 and 3(42.9%) cases showed moderate expression.  In the moderately 
advanced stage, 1(33.3%) case had mild expression for Cx43 and 2(66.7%) 
cases had moderate expression of Cx43. None of the cases were in the advanced 
stage of OSF. There was no significant difference in the staining intensity 
between the different stages of OSF (p=0.431)  
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Comparison of Cx43 staining of suprabasal cell layer among the different 
grades of epithelial dysplasia (Table X & Graph X):- 
The cases of epithelial dysplasia were graded as mild, moderate and severe. In 
cases of mild dysplasia, 2(33.3%) cases showed no expression of Cx43, 
2(33.3%) cases showed a mild expression of Cx43 and 2(33.3%) cases showed a 
moderate expression of Cx43. Among the cases of moderate dysplasia, 3(50%) 
cases showed no expression of Cx43, 2(33.3%) cases showed mild expression of 
Cx43 and 1(16.7%) case had a moderate staining for Cx43. None of the cases in 
the study group had severe dysplasia. The difference in staining intensity of the 
suprabasal layer between different grades of dysplasia was not significant 
(p=0.766). 
 
Distribution of Cx43 staining of basal and suprabasal cell layers among the 
study groups. (Table XI & Graph XI):- 
Comparing the basal cell layer staining among the study groups, group II showed 
expression  in 4(28.6%) cases(p=0.047).  The suprabasal cell layer staining  in  
the study groups showed that , group I had a positive expression in 5(83.3%) 
cases, group II in 12(85.7%), group III in 7(58.3%) and group IV in 2(28.6%)  
cases, respectively (p=0.046). 
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Distribution of Cx43 staining between group II (OSF) and group IV (OSCC 
with history of OSF) (Table XII & Graph XII):- 
In group II, 13(92.9%) cases had expression of Cx43 and 1(7.1%) cases did not 
express Cx43. In group IV, 6(85.7%) cases had expression of Cx43 and 1 (14.3%) 
case had no Cx43 expression. The difference in Cx43 staining was not significant 
between group II and IV (p=1.0). 
 
Comparison of Cx43 staining intensity of basal cell layer between group II 
(OSF) and group IV (OSCC with history of OSF) (Table XIII & Graph 
XIII):- 
In group II, 10(71.4%) cases showed no expression in the basal cell layer, 
3(21.4%) cases showed a mild expression of Cx43 and 1(7.1%) case showed a 
moderate expression. In group IV were cases of OSF with history of OSCC, all 
7(100%) of the cases showed no expression of Cx43 in the basal cell layer. The 
difference in Cx43 staining of the basal cell layer was not statistically significant 
(p=0.291). 
 
Comparison of Cx43 staining intensity of suprabasal cell layer between 
group II (OSF) and group IV (OSCC with history of OSF) (Table XIV & 
Graph XIV):- 
In group II, 2(14.3%) cases showed no expression of Cx43 while 7(50%) cases 
showed a mild expression and 5(35.7%) cases showed a moderate expression. In 
group IV, 5(71.4%) cases showed no expression of Cx43, 1(14.3%) case showed 
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a mild Cx43 expression and 1(14.3%) case had anintense expression of Cx43. 
The difference in suprabasal layer staining intensity was statistically significant 
between groups II and IV (p=0.014). 
 
Comparison of Cx43 staining intensity of connective tissue between group II 
(OSF) and group IV (OSCC with history of OSF) (Table XV& Graph XV):- 
 In group II, there was 1(7.1%) case which showed no expression of Cx43, 
5(35.7%) cases showed a mild expression, 7(50%) casesshowed a moderate 
expression of Cx43 and 1(7.1%) case showed anintense expression of Cx43. In 
group IV, 5(71.4%) cases showed a mild Cx43 expression while 1(14.3%) case 
showed moderate expression and 1(14.3%) case showed anintense expression of 
Cx43. The difference in connective tissue staining between groups II and IV was 
not significant (p=0.313). 
 
Comparison of Cx43 staining intensity of basal cell layer between group II 
(OSF) and group III (Epithelial dysplasia) (Table XVI & Graph XVI):- 
 In group II, 10(71.4%) cases did not show the expression for Cx43, 
3(21.4%)showed a mild expression and 1(7.1%) case showed a moderate 
expression of Cx43. In group III, all 12(100%) cases showed no expression of 
Cx43. The difference in basal layer staining intensity between the groups II and 
II was not significant (p=0.132). 
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Comparison of Cx43 staining intensity of suprabasal cell layer between 
group II (OSF) and group III (Epithelial dysplasia) (Table XVII & Graph 
XVII):- 
 In group II 2(14.3%) cases showed no expression of Cx43, while 7(50%) 
cases showed a mild expression and 5(35.7%) casesshowed a moderate 
expression for Cx43. In group III, 5(41.7%) cases showed no expression of 
Cx43, 4(33.3%) showed a mild expression of Cx43 and 3(25%) showed a 
moderate expression of Cx43. The difference in suprabasal layer staining 
between the groups II and III was not significant (p=0.292). 
 
Comparison of Cx43 staining intensity of connective tissue between group II 
(OSF) and group III (Epithelial dysplasia) (Table XVIII & Graph XVIII):- 
 In group II, 1(7.1%) showed no expression of Cx43, 5(35.7%) cases 
showed a mild expression of Cx43, 7(50%) cases showed a moderate expression 
and 1(7.1%) case showed an intense expression of Cx43. In group III, 4(33.3%) 
did not show any expression of Cx43, 5(41.7%) cases showed a mild expression 
of Cx43 and 3(25%) cases showed a moderate expression of Cx43. The 
difference in connective tissue staining between groups II and III was not 
significant (p=0.234). 
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Distribution of Cx43 staining between group III (Epithelial dysplasia) and 
group IV (OSCC with history of OSF) (Table XIX & Graph XIX):- 
 In group III, 8(66.7%) cases had an expression of Cx43 while 4(33.3%) 
had no expression of Cx43. In group IV, 6(85.7%) cases had expression for 
Cx43 and 1(14.3%) had no expression of Cx43. The difference in Cx43 staining 
between groups III and IV was not significant (p=0.363). 
 
Comparison of Cx43 staining intensity of basal cell layer between group III 
(Epithelial dysplasia) and group IV (OSCC with history of OSF) (Table XX 
& Graph XX):- 
  In group III and group IV, all 12 (100%) cases and 7 
(100%)showed no expression of Cx43(p=1.0). 
 
Comparison of Cx43 staining intensity of suprabasal cell layer between 
group III (Epithelial dysplasia) and group IV (OSCC with history of 
OSF)(Table XXI & Graph XXI):- 
 In group III, 5(41.7%) of cases showed no expression of Cx43, 4(33.3%) 
of the cases showed a mild expression and 3(25%) of cases showed a moderate 
expression of Cx43. In group IV, 5(71.4%) cases had no expression of Cx43 
while 1(14.3%) cases showed a mild expression of Cx43 and 1(14.3%) showed 
an intense expression for Cx43. The difference in suprabasal layer staining 
intensity between groups III and IV was not significant (p=0.186). 
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Comparison of Cx43 staining intensity of Connective tissue between group 
III(Epithelial dysplasia) and group IV (OSCC with history of OSF)(Table 
XXII & Graph XXII):- 
In group III, there were 4(33.3%) cases that showed no expression of 
Cx43, 5(41.7%) cases showed a mild expression of Cx43 and 3(25%) cases 
showed a moderate expression for Cx43. In group IV, 5(71.4%) cases showed a 
mild expression while 1(14.3%) case showed a moderate expression and 
1(14.3%) case showed intense expression of Cx43. The difference in connective 
tissue staining intensity between groups III and IV was not significant (p=0.169). 
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TABLE I: AGE DISTRIBUTION AMONG THE STUDY GROUPS (N=39) 
 
 
 
 
GRAPH I: AGE DISTRIBUTION AMONG THE STUDY GROUPS (N=39) 
 
 
 
 
GROUP I    : NORMAL MUCOSA (n=6) 
GROUP II   : ORAL SUBMUCOUS FIBROSIS (n=14) 
GROUP III : EPITHELIAL DYSPLASIA (n=12) 
            GROUP IV : OSCC WITH HISTORY OF OSF (n=7) 
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TABLE II: GENDER DISTRIBUTION AMONG THE STUDY GROUPS 
(N=39) 
 
 
 
GENDER 
 
GROUP I 
(n=6) 
 
GROUP II 
(n=14) 
 
GROUP III 
(n=12) 
 
GROUP IV 
(n=7) 
p 
value 
 
MALE 
 
4(66.7%) 
 
10(71.4%) 
 
11(91.7%) 
 
6(85.7%) 
 
 
0.490  
FEMALE 
 
2(33.3%) 
 
4(28.6%) 
 
1(8.3%) 
 
1(14.3%) 
 1 
 
GRAPH II : GENDER DISTRIBUTION AMONG THE STUDY GROUPS 
(N=39) 
 
 
 
 
 
 
 
 
 
GROUP I     : NORMAL MUCOSA (n=6) 
GROUP II   : ORAL SUBMUCOUS FIBROSIS (n=14) 
GROUP III : EPITHELIAL DYSPLASIA (n=12) 
            GROUP IV : OSCC WITH HISTORY OF OSF (n=7) 
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TABLE III: DISTRIBUTION OF HABITS AMONG THE STUDY GROUPS 
(N=39) 
 
  
GROUP I 
(n=6) 
 
GROUP II 
(n=14) 
 
GROUP 
III 
(n=12) 
 
GROUP 
IV 
(n=7) 
 
p 
value 
 
NO HABITS 
 
6(100%) 
 
0(0%) 
 
0(0%) 
 
0(0%) 
 
 
 
 
 
 
 
 
 
 
0.000** 
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CHEWING 
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0(0%) 
 
7(58.3%) 
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ARECA NUT 
+TOBACCO 
 
0(0%) 
 
5(35.7%) 
 
1(8.3%) 
 
4(57.1%) 
SMOKING+ 
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0(0%) 
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4(33.3%) 
 
1(14.3%) 
SMOKING + 
TOBACCO 
CHEWING+ARECA 
NUT CHEWING 
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2(28.6%) 
 
**p<0.01 
 
GRAPH III: DISTRIBUTION OF HABITS AMONG THE STUDY 
GROUPS (N=39) 
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TABLE IV: DISTRIBUTION OF SITE OF LESION AMONG THE STUDY 
GROUPS (N=39) 
 
 
 
SITE 
 
GROUP I 
(n=6) 
 
GROUP II 
(n=14) 
 
GROUP III 
(n=12) 
 
GROUP IV 
(n=7) 
 
   p 
value 
 
BUCCAL 
MUCOSA 
 
3(50%) 
 
14(100%) 
 
12(100%) 
 
 
3(42.9%) 
 
 
 
 
 
0.001** 
 
ALVEOLAR 
MUCOSA 
 
3(50%) 
 
0(0.0%) 
 
0(0.0%) 
 
1(14.3%) 
 
PALATE 
 
0(0.0%) 
 
0(0.0%) 
 
0(0.0%) 
 
1(14.3%) 
 
TONGUE 
 
 
0(0.0%) 
 
0(0.0%) 
 
0(0.0%) 
 
2(28.6%) 
   
 **p<0.01 
 
 
GRAPH IV: DISTRIBUTION OF SITE OF THE LESION 
AMONG THE STUDY GROUPS (N=39) 
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TABLE V: DISTRIBUTION OF STAINING OF Cx43 AMONG THE 
STUDY GROUPS (N=39) 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRAPH V: DISTRIBUTION OF STAINING OF Cx43 AMONG THE 
STUDY GROUPS (N=39) 
 
 
 
 
 
 
GROUP I    : NORMAL MUCOSA (n=6) 
GROUP II   : ORAL SUBMUCOUS FIBROSIS (n=14) 
GROUP III : EPITHELIAL DYSPLASIA (n=12) 
            GROUP IV : OSCC WITH HISTORY OF OSF (n=7) 
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TABLE VI: COMPARISON OF Cx43 STAINING INTENSITY OF 
BASAL LAYER AMONG THE STUDY GROUP (N=39) 
 
 
 
GROUP I 
(n=6) 
 
GROUP II 
(n=14) 
 
GROUP 
III 
(n=12) 
 
GROUP 
IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
6(100%) 
 
10(71.4%) 
 
12(100%) 
 
7(100%) 
 
 
 
 
 
0.241 
 
MILD 
 
0(0%) 
 
 
3(21.4%) 
 
 
0(0%) 
 
 
0(0%) 
 
 
MODERATE 
 
0(0.0%) 
 
 
1(7.1%) 
 
0(0%) 
 
 
0(0.0%) 
 
 
INTENSE 
 
0(0.0%) 
 
 
0(0%) 
 
 
0(0.0%) 
 
 
0(0%) 
 
 
 
GRAPH VI: COMPARISONOF Cx43 STAINING INTENSITY OF 
BASAL LAYER AMONG THE STUDY GROUP (N=39) 
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TABLE VII: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER AMONG THE STUDY GROUP (N=39) 
 
 
 
GROUP I 
(n=6) 
 
GROUP II 
(n=14) 
 
GROUP 
III 
(n=12) 
 
GROUP IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
1(16.7%) 
 
 
2(14.3%) 
 
 
5(41.7%) 
 
 
5(71.4%) 
 
 
 
 
 
0.033* 
 
MILD 
 
5(83.3%) 
 
7(50%) 
 
4(33.3%) 
 
1(14.3%) 
 
MODERATE 
 
0(0.0%) 
 
 
5(35.7%) 
 
 
3(25%) 
 
0(0%) 
 
INTENSE 
 
0(0.0%) 
 
 
0(0.0%) 
 
 
0(0.0%) 
 
 
1(14.3%) 
 
 
 *p<0.05 
 
GRAPH VII: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER AMONG THE STUDY GROUP (N=39) 
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TABLE VIII: COMPARISON OF Cx43 STAINING INTENSITY IN THE 
CONNECTIVE TISSUE AMONG THE STUDY GROUP (N=39) 
 
 
 
GROUP I 
(n=6) 
 
GROUP 
II 
(n=14) 
 
GROUP 
III 
(n=12) 
 
GROUP 
IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
1(16.7%) 
 
1(7.1%) 
 
4(33.3%) 
 
0(0%) 
 
 
 
 
0.279 
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4(66.7%) 
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GRAPH VIII: COMPARISON OF Cx43 STAINING INTENSITY IN THE 
CONNECTIVE TISSUE AMONG THE STUDY GROUP (N=39) 
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TABLE IX: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER AMONG DIFFERENT GRADES OF ORAL 
SUBMUCOUS FIBROSIS (GROUP-II) (N=14) 
 
 
VERY 
EARLY 
STAGE 
(n=4) 
EARLY 
STAGE 
(n=7) 
MODERATELY 
ADVANCED 
STAGE 
(n=3) 
ADVANCED 
STAGE 
(n=0) 
p 
value 
NO 
EXPRESSION 
 
1(25%) 
 
1(14.3%) 
 
 
0(0%) 
 
 
0(0%) 
 
 
 
 
0.431 
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GRAPH IX: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER AMONG THE DIFFERENT GRADES OF 
ORAL SUBMUCOUS FIBROSIS (GROUP-II) (N=14) 
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TABLE X: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER AMONG DIFFERENT GRADES OF 
EPITHELIAL DYSPLASIA (GROUP-III) (N=12) 
 
 
 
MILD 
DYSPLASIA 
(n=6) 
MODERATE 
DYSPLASIA 
(n=6) 
SEVERE 
DYSPLASIA 
(n=0) 
 
p 
value 
NO 
EXPRESSION 
2(33.3%) 3(50.0%) 0(0%) 
 
 
 
0.766 
MILD 2(33.3%) 2(33.3%) 0(0%) 
MODERATE 2(33.3%) 1(16.7%) 0(0%) 
INTENSE 0(0%) 0(0%) 0(0%) 
 
 
 
GRAPH X: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER AMONG THE DIFFERENT GRADES OF 
EPITHELIAL DYSPLASIA (GROUP-III) (N=12) 
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TABLE XI: DISTRIBUTION OF Cx43 STAINING OF BASAL AND 
SUPRABASAL CELL LAYERS AMONG THE STUDY GROUPS (N=39) 
 
 
GRAPH XI : DISTRIBUTION OF Cx43 STAINING OF BASAL AND 
SUPRABASAL CELL LAYERS AMONG THE STUDY GROUPS (N=39) 
GROUP I     : NORMAL MUCOSA (n=6) 
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GROUP III : EPITHELIAL DYSPLASIA (n=12) 
GROUP IV : OSCC WITH HISTORY OF OSF (n=7) 
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TABLE XII: DISTRIBUTION OF STAINING OF Cx43 BETWEEN GROUP 
II AND GROUP IV (N=21) 
 
 
 
 
 
 
 
 
 
 
 
 
GRAPH XII: DISTRIBUTION OF STAINING OF Cx43  
BETWEEN GROUP II AND GROUP IV (N=21) 
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TABLE XIII: COMPARISON OF Cx43 STAINING INTENSITY OF BASAL 
CELL LAYER BETWEEN GROUP II AND GROUP IV (N=21) 
 
 
 
GROUP II 
(n=14) 
 
GROUP 
IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
   
10(71.4%) 
 
7(100%) 
 
 
 
 
 
0.291 
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GRAPH XIII: COMPARISON OF Cx43 STAINING INTENSITY OF 
BASAL CELL LAYER BETWEEN GROUP II AND GROUP IV (N=21) 
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TABLE XIV: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER BETWEEN GROUP II AND GROUP IV 
(N=21) 
 
 
 
GROUP II 
(n=14) 
 
GROUP IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
2(14.3%) 
 
 
5(71.4%) 
 
 
 
 
 
0.014* 
 
MILD 
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1(14.3%) 
` 
MODERATE 
 
5(35.7%) 
 
 
0(0%) 
INTENSE 
 
0(0.0%) 
 
 
1(14.3%) 
 
 
 
 
GRAPH XIV: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER BETWEEN GROUP II AND GROUP IV 
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TABLE XV: COMPARISON OF Cx43 STAINING INTENSITY IN THE 
CONNECTIVE TISSUE BETWEEN GROUP II AND GROUP IV (N=21) 
 
 
 
GROUP II 
(n=14) 
 
GROUP IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
1(7.1%) 
 
0(0%) 
 
 
 
 
0.313 
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GRAPH XV: COMPARISON OF Cx43 STAINING INTENSITY IN THE 
CONNECTIVE TISSUE BETWEEN GROUP II AND GROUP IV (N=21) 
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TABLE XVI: COMPARISON OF Cx43 STAINING INTENSITY OF BASAL 
CELL LAYER BETWEEN GROUP II AND GROUP III (N=21) 
 
 
 
GROUP II 
(n=14) 
 
GROUP III 
(n=12) 
 
p 
value 
 
NO 
EXPRESSION 
 
10(71.4%) 
 
 
12(100%) 
 
 
 
 
 
0.132 
 
MILD 
 
3(21.4%) 
 
0(0%) 
` 
MODERATE 
 
1(7.1%) 
 
 
0(0%) 
INTENSE 
 
0(0.0%) 
 
 
0(0%) 
 
 
 
 
GRAPH XVI: COMPARISON OF Cx43 STAINING INTENSITY OF 
BASAL CELL LAYER BETWEEN GROUP II AND GROUP III 
 
 
GROUP II   : ORAL SUBMUCOUS FIBROSIS (n=14) 
            GROUP III : EPITHELIAL DYSPLASIA (n=12) 
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TABLE XVII: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER BETWEEN GROUP II AND GROUP III 
(N=26) 
 
 
GROUP 
II 
(n=14) 
 
GROUP 
III 
(n=12) 
 
p 
value 
 
NO 
EXPRESSION 
 
2(14.3%) 
 
 
5(41.7%) 
 
 
 
 
 
0.292 
 
MILD 
 
7(50%) 
 
4(33.3%) 
` 
MODERATE 
 
5(35.7%) 
 
 
3(25%) 
INTENSE 
 
0(0.0%) 
 
 
0(0%) 
 
 
 
GRAPH XVII: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER BETWEEN GROUP II AND GROUP III 
(N=26) 
 
 
GROUP II  : ORAL SUBMUCOUS FIBROSIS (n=14) 
            GROUP III : EPITHELIAL DYSPLASIA (n=12) 
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TABLE XVIII: COMPARISON OF Cx43 STAINING INTENSITY OF 
CONNECTIVE TISSUE INTENSITY BETWEEN GROUP II AND GROUP 
III (N=26) 
 
 
GROUP II 
(n=14) 
 
GROUP III 
(n=12) 
 
p 
value 
 
NO 
EXPRESSION 
 
1(7.1%) 
 
 
4(33.3%) 
 
 
 
 
 
0.234 
 
MILD 
 
5(35.7%) 
 
5(41.7%) 
` 
MODERATE 
 
7(50%) 
 
 
3(25%) 
INTENSE 
 
1(7.1%) 
 
 
0(0%) 
 
 
 
 
GRAPH XVIII: COMPARISON OF Cx43 STAINING INTENSITY OF 
CONNECTIVE TISSUE BETWEEN GROUP II AND GROUP III (N=26) 
 
GROUP II : ORAL SUBMUCOUS FIBROSIS (n=14) 
            GROUP III: EPITHELIAL DYSPLASIA (n=12) 
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TABLE XIX: DISTRIBUTION OF Cx43 STAINING BETWEEN  
GROUP III AND GROUP IV (N=19) 
 
 
 
GROUP 
III 
(n=14) 
 
GROUP IV 
(n=12) 
 
p 
value 
 
PRESENT 
 
8(66.7%) 
 
 
6(85.7%) 
 
 
0.363  
ABSENT 
 
4(33.3%) 
 
1(14.3%) 
 
 
 
GRAPH XIX: DISTRIBUTION OF Cx43 STAINING BETWEEN GROUP 
III AND GROUP IV (N=19) 
 
 
GROUP III : ORAL SUBMUCOUS FIBROSIS (n=14) 
            GROUP IV : OSF WITH HISTORY OF OSCC (n=7) 
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TABLE XX: COMPARISON OF Cx43 STAINING INTENSITY OF BASAL 
CELL LAYER BETWEEN GROUP III AND GROUP IV (N=19) 
 
 
GROUP 
III 
(n=12) 
 
GROUP IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
12(100%) 
 
 
7(100%) 
 
 
 
 
 
1.0 
 
MILD 
 
0(0%) 
 
 
0(0%) 
` 
MODERATE 
 
0(0%) 
 
 
0(0%) 
INTENSE 
 
0(0.0%) 
 
 
0(0%) 
 
 
 
GRAPH XX - COMPARISON OF Cx43 STAINING INTENSITY OF BASAL 
CELL LAYER BETWEEN GROUP III AND GROUP IV 
 
GROUP III : EPITHELIAL DYSPLASIA (n=12) 
            GROUP IV : OSF WITH HISTORY OF OSCC (n=7) 
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TABLE XXI: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER INTENSITY BETWEEN GROUP III AND 
GROUP IV (N=19) 
 
 
GROUP 
III 
(n=12) 
 
GROUP IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
5(41.7%) 
 
5(71.4%) 
 
 
 
 
 
0.186 
 
MILD 
 
4(33.3%) 
 
1(14.3%) 
` 
MODERATE 
 
3(25%) 
 
 
0(0%) 
INTENSE 
 
0(0.0%) 
 
 
1(14.3%) 
 
 
 
 
GRAPH XXI: COMPARISON OF Cx43 STAINING INTENSITY OF 
SUPRABASAL CELL LAYER BETWEEN GROUP III AND GROUP IV 
(N=19) 
GROUP III : EPITHELIAL DYSPLASIA (n=12) 
            GROUP IV : OSF WITH HISTORY OF OSCC (n=7) 
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TABLE XXII: COMPARISON OF Cx43 STAINING INTENSITY OF 
CONNECTIVE TISSUE BETWEEN GROUP III AND GROUP IV (N=19) 
 
 
 
 
 
 
GROUP 
III 
(n=12) 
 
GROUP IV 
(n=7) 
 
p 
value 
 
NO 
EXPRESSION 
 
4(33.3%) 
 
     0(0%) 
 
 
 
 
 
0.169 
 
MILD 
 
5(41.7%) 
 
5(71.4%) 
` 
MODERATE 
 
3(25%) 
 
 
1(14.3%) 
INTENSE 
 
0(0.0%) 
 
 
1(14.3%) 
 
 
 
GRAPH XXII: COMPARISON OF Cx43 STAINING INTENSITY OF 
CONNECTIVE TISSUE BETWEEN GROUP III AND GROUP IV (N=19) 
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Oral squamous cell carcinoma (OSCC) accounts for almost 90% of the 
malignancies that occur in the head and neck regions.74They are seen in various 
parts of the oral cavity such as buccalmucosa, tongue, floor of the mouth, palate 
and the oropharyngealregions.75OSCC that are seen in the South-East Asian 
countries are frequently associated withthe habits of areca nut chewing, tobacco 
chewing and alcohol consumption. The incidence of OSCC is on the rise and they 
have a reduced over-all 5 year survival rate as majority of the cancers are 
diagnosed at an advanced stage.76 
 OSCCs are precededby lesions, now referred as Oral Potentially 
Malignant Disorder (OPMDs) that carry a risk for malignant 
transformation.33TheseincludeLeukoplakia, Erythroplakia and Oral submucous 
fibrosis (OSF). Not all of these lesions proceed to oral squamous cell 
carcinoma.Among them,Leukoplakia which refers to white patches seen clinically 
are one of the most commonly seen OPMD. It has a global prevalence rate of 
2.6%, with a malignant transformation rate of 1.36% per 
year.77Histopathologically, the condition exhibits dysplastic features in the 
epithelium. It is frequently associated with the habit of tobacco chewing and 
smoking. Buccal mucosa is the most commonly involved site for epithelial 
dysplasia.78 The epithelial dysplasia observed histologically can be graded into 
mild, moderate and severe based on the cytological and architectural features 
based on the WHO criteria.3 
 OSF is very common in the Indian sub-continent and is associated with the 
habit of areca nut chewing.19Various studies have been carried out to understand 
the mechanism of the underlying fibrosis. OSF is characterized by stiffening and 
formation of palpable fibrotic bands that leadto a reduction in mouth opening. 
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Histopathologically, OSF is a connective tissue disorder characterized by 
excessive collagen deposition and juxta-epithelial hyalinization. The epithelium 
associated with OSFwas thought to be atrophic but it has been suggested that as 
OSF advances, the features of epithelial dysplasia are more evident in the 
epithelium.10 Different stages of OSF demonstrate varying epithelial thickness 
with features of basal cell hyperplasia and hyperkeratosis.79 
 Connexins are trans-membranous proteins that connect the cytoplasm of 
one cell to the other and form the gap junction. These junctions are responsible for 
the communication between adjacent cells in sharing secondary messengers, 
growth factors and ions. In humans, 21 isoforms of connexins have been 
identified. Among them, Connexin43 (Cx43) has been found to be expressed in 
majority of the tissues.52Together with each connexon molecule, they form GJIC 
(Gap Junctional Intercellular Communication Channel), through which secondary 
messengers, ions and growth factors are exchanged between the adjacent cells. 
Reduction of gap junctions and their channels play an important role in 
tumorinitiation, progression and migration of the neoplastic cells, thereby 
facilitating cellular invasion and metastasis.73In this study, weanalysed the pattern 
of Cx43expression among OSF cases, comparing them with that of the expression 
seen in epithelial dysplasia, in cases of OSCC that were associated with a 
historyof OSF and normal mucosa which is the control group. 
 Archival blocks were used as samples in the study groups. There was a 
significant difference in the distribution of age among the study groups. We 
observed thatin group I (control group), 1(17%) cases was< 25 years of age and 
5(83.3%) cases were between 25-50 years of age. In group II, (OSF), there were 
7(50%) cases within 25-50 years of age and 7(50%) cases were > 50 years of age. 
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The occurrence of OSF in the younger age group findings was consistent with the 
findings of the study by Ranganathan et al who stated that OSF was 
predominantly seen in a younger population.19 In group III (epithelial dysplasia), 
6(50%) cases were within 25-50 years of age and 6(50%) cases were > 50 years of 
age.This was in agreement by findings of the study by Silverman et al who 
described that epithelial dysplasia iscommon in the younger age group, among 
those associated with the habit of tobacco chewing and smoking which continues 
to be persistent for many years to continuation of the tobacco chewing habit.78 In 
group IV (OSCC with history of OSF), 5(71.4%) cases were> 50 years of 
age.This finding was consistent with the findings of the study done by Mehrotraet 
alwho stated that OSCC prevalence was likely to be more, in those above 50 years 
of age due to the long duration of chewing habit.80 There were 2(28.6%) cases in 
the age 25-50 years of age. This finding was in agreement with the findings of 
studies by Chaturvedi et al and Sarode et al who stated that OSCC arising in the 
background of OSF was common in the younger age group.36,81 Recently, Balaji 
et alhad reported one case of well-differentiated OSCC, in a 32-year old male 
with a history of OSF and areca-nut chewing.82 
 Considering the gender distribution,male population were predominantly 
seen in all study groups. In group II (OSF),a majority of the cases (71.4%) were 
males. This was in line with the findings of the study done by Hazarey et al who 
reported a similar male to female ratio of 4.9:1 and Ranganathan et al who had 
also observed a male to female ratio of 6:1 in a clinico-pathological study of OSF 
cases.83,79 In group III (epithelial dysplasia),91.7% of cases were males. This was 
in agreement with the findings of the study by Petti et al who observed a male 
predilection for epithelial dysplasia, owing to the higher prevalence of tobacco 
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chewing and cigarette smoking habits among them.77In group IV, there were 
6(85.7%) males diagnosed with OSCC with a history of OSF. This was in 
agreement with the findings of the study done by Sarode et al who stated that 
given the prevalence of areca nut chewing habit more among males, compared to 
females, the occurrence of OSF with OSCC showed the same trend.81 
 OSF is commonly seen in those with the habit of areca nut chewing as the 
constituents of areca nut is thought to promote the fibrotic 
pathogenesis.Thedistribution of type of habits between the study groups was 
found to be statistically significant.in group II (OSF)9(64.3%) cases had the habit 
of areca nut chewing. This finding was consistent with studies by Sinor PN et al 
and Ranganathan et al who had stated that OSF was predominantly associated 
with the habit of areca nut chewing.84,79 In group III (epithelial dysplasia), 
7(58.3%) cases had the habit of tobacco chewing while 4(33.3%) caseshad the 
habit of smoking along with arecanut chewing. This was in agreement with the 
findings of the study by Silverman et alwho observed that majority of the 
population who had epithelial dysplasia were associated with the habit of tobacco 
usage.78In group IV (OSCC with history of OSF),4(57%) cases had the habit of 
chewing areca nut with tobacco, 1(14.3%) case had the habit of smoking, 
concurrent with areca-nut and tobacco chewing and 1(14.3%) case had the habit 
of areca nut chewing and smoking. This finding was in agreement with IARC 
statement that the mixture of tobacco products with areca nut could increase the 
risk of malignancy.5 
 In this study, the most common site of the lesions was the buccal mucosa. 
In group II (OSF) and in group III (epithelial dysplasia) all the cases were from 
buccal mucosa and 12(100%) of the cases of group III (epithelial dysplasia) were 
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from buccal mucosa. This finding was in agreement with the study by Kanodia et 
alwho stated that majority of the cases of OSF occurred in the buccal mucosa due 
to long term contact of areca nut with buccal mucosa and Petti et al who described 
that epithelial dysplasia were more prevalent in the buccal mucosa.77,85In group IV 
(OSCC with history of OSF), 3(42.9%) cases were from buccal mucosa, 1(14.3%) 
from alveolar mucosa, 1(14.3%)was from the palate and 2(28.6%) cases from the 
tongue.The pattern of distribution of the site of the lesion between the groups was 
statistically significant which could be related for the prevalence of the particular 
habit, which could be considered as the etiological event (p=0.001). 
 Oral epithelial cells displayed intercellular gap junctions just as most other 
epithelial cells.In their study, Xia et al stated that in normal epithelia, Cx43 
staining was mainly seen in the cell membrane and was weak in the basal cell 
layer. The staining was also seen more predominantly in stratum spinosum and 
stratum granulosum and was negative in the stratum corneum.68So far, there are 
no published reports, analyzing the Cx43 expression in oral submucous fibrosis 
and oral epithelial dysplasia. 
 On examining the overall staining pattern of Cx43 among the study 
groups, in Group 1 (Control group), 83% of cases expressed Cx43. In Groups I 
that is the control group, the absence of the staining can be attributed to the fact 
that the tissue was obtained from inflamed gingiva. This was in agreement with 
findings of Fernandez-Cobo et al who observed that gap junctional proteins were 
lost in inflammatory process. In group II, 93% of the cases expressed Cx43 
staining, the once case which did not express in the epithelium was found to have 
moderate dysplasia.86 
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 In Group III (epithelial dysplasia), expression for Cx43 was seen in 67% 
of the cases and in 4 cases (33 %) there was no expression and when we analysed 
the histopathology of these four cases, we found that they presented with 
moderate dysplasia of the epithelium. Trond Aasen et al reported the loss of gap 
junctional protein Cx43in dysplastic cervix and stated that this was primarily due 
to the reduced expression.87 We extend the above explanation for the absence of 
expression in once case of group II, since the epithelium of the OSF case was 
dysplastic. In Group IV, only one case showed Cx43 expression in both the 
surface epithelium and in the infiltrating islands in the connective tissue. 
 In group II, 5 cases expressed Cx43 in the connective tissue and was in 
close proximity to the epithelial cells. The expression in the connective tissue is 
explained as follows, in addition to the gap junction function, connexins have also 
been found to have transcriptional function which is independent of the 
intercellular communication process.88 The authors reported that cell mediated 
contact signalling is important in carcinogenesis. They also stated that epithelial 
stromal interactions and signalling are also critical for normal cell biology, cancer 
cell migration and for the expression of connexins in the connective tissue in 
neoplastic progression. 
 When we analysed the expression of Cx43 in different layers of the 
epithelium, we found that none of the cases expressed positivity in the basal layer 
in Group I, Group III and Group IV while in Group II, 4 cases showed mild to 
moderate expression (29%). The absence of expression in the basal layer of the 
control tissue can be explained given the fact the basal cells of the normal 
epithelia might have developed less gap junctions than the cells in the stratum 
spinosum and granulosum.68The absence of staining in Group III and IV could be 
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explainedby the hypothesis of Xia et al that dysplastic epithelium displayed 
decreased Cx43 expression which parallel the progression of oral carcinogenesis. 
68Given the above fact, the presence of staining in 29% of Group II cases may 
reflect the alteration in the basal layer staining compared to the normal epithelia. 
In these 4(29%) of the cases of OSF group, the epithelium was moderately 
dysplastic. This finding could be a key factor in the progression of dysplasia to 
malignancy.     Supra-basal staining of Cx43 was 
observed in all the groups and the difference in the percentage of positivity of 
cases was statistically significant between the groups.83% of controls (Group I) 
expressed Cx43 in the supra basal layer, but were of only mild intensity, as stated 
by Xia et al. 
 The percentage of positivity was maximum in OSF group (group II)(86%), 
of which 36% had moderate intensity. In our study, in group II, it was interesting 
to find that, four cases (28%)expressed staining in both basal and supra basal 
layers and this pattern of staining throughout the thickness of the epithelium was 
unique to Group II (OSF).We compared the Cx43 expression among the OSF 
cases which were graded according to the histopathological criteria given by 
Pindborg & Sirsat et al as very early stage, early stage, moderately early stage 
and advanced stage (Table IX).13When we analyzed the staining intensity of Cx43 
among the different grades of OSF, the distribution of intensity of staining was 
not statistically significant.  
 In group III, 58% of the cases expressed staining, of which 25% had 
moderate intensityand there was no statistically significant difference between 
grades of dysplasia (Table X).The loss of Cx43 expression seen in dysplastic 
conditions was studied by Mese et al who stated that during early stages of the 
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dysplastic conditions, the gap junctions try to establish homeostasis by exchange 
of messengers and growth factors between normal adjacent cells.89 In our study, 
we did not find a statistically significant difference in the Cx43 expression in the 
supra-basal layer between the different stages of OSF and different grades of 
dysplasia.  
 With regard to the expression of Cx43 in Group IV (OSCC), only two 
cases (28.6%) showed Cx43 expression in both the surface epithelium and the 
infiltrating epithelial islands in the connective tissue. The remaining 6 cases 
(71.4%) exclusively showed Cx43 positivity in the fibroblasts of the connective 
tissue only.  
 Among the groups, the connective tissue expression of Cx43 was mild in 
groups I (normal mucosa), III (epithelial dysplasia) and IV (OSCC with OSF) 
while in group II, moderate intensity of staining was seen in 50% of cases which 
was more than that observed in group III (25%), group IV(14.3%) and group I 
(16.7%). This high expression of Cx43 in the connective tissue was observed by 
Pistorio et al who stated that GJIC might allow exchange of αSMA between the 
fibroblast and mast cells, resulting in increased fibrosis.90 This increased 
acquisition of αSMA, a mesenchymal marker, transferred through the GJIC 
between the fibroblasts might predispose the basal cell layer to a future type II 
epithelial-mesenchymal transitional event.91 
 Inour study, the expression of Cx43 was observedin two cases of OSCC. 
In studies done by Tanaka et al, Tang et al, and Juan Xia et al., there was a 
decrease in Cx43 expression,associated with carcinogenesis.62,64,68 1(50%) case of 
a moderately differentiated OSCC showed an intense expression of Cx43 in the 
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connective tissue. The presence of intense staining in this case could be explained 
by the findings of Han et al who stated that increased expression levels of Cx43 is 
seen in the advancing stages of colonic carcinoma which supports the role of 
Cx43 in tumor progression and metastatic capacity.88Jamieson et al in their study 
also had found increased expression ofCx43levels in breast cancer.92 
 When we compared the basal layer staining across the groups, 4 cases of 
group II (29%)showed expression of Cx43 and there was no staining observed in 
groups I, III and IV (Table XI, p=0.047). These four cases in group II, were also 
found to show the expression in the supra-basal layer. In all the other groups, only 
the supra-basal layer expressed Cx43 (Group I: 83%,group III: 58% and Group 
IV: 29%). This difference in staining pattern was statistically significant. (p = 
0.046).We also observed that only in group II (OSF), the staining pattern was seen 
in the basal and the supra basal layers corresponding to the entire thickness of the 
epithelium.  
 When we compared the distribution of Cx43 expression and staining 
intensity of the basal cell layer, between groups II and IV, there was no significant 
difference; but when we compared the expression in the supra basal layer, we 
found that 50% of cases in group II and 14 % of cases in group IV showed mild 
staining, 36 % of group II had moderate staining and 14% of group IV had intense 
staining (Table XII to Table XIV).So the observation from this finding, supports 
the fact that there is a decrease in the Cx43 expression in OSCC with OSF than in 
OSF. It could be hypothesised that with malignant transformation of the OSF, 
there is a loss of Cx43 expression. 
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 When we compared the intensity of expression of Cx43 between groups II 
(OSF) and Group IV (OSCC) in the connective tissue, there was no significant 
difference. Analysis of Cx43 staining intensity of the basal layer, supra basal layer 
and connective tissue, when compared between groups II and III and groupsIII 
and IV, was not found to be statistically significant(Table XV to XXII). 
 From the above findings, we state that Cx43 expression can be seen in the 
normal epithelia as stated by Trosko and Ruch, such as those of skin, oesophagus, 
cervix, prostate, lung and CNS. Reduced expression or aberrant location of Cx43 
protein or even loss of Cx43 expression has been reported in tumours arising from 
the epithelia of these tissues.93Livny et alreported that in normal oral mucosal 
cells, the expression of Cx43 was high when compared to that of oral cancer 
cells.94Gitenay et alstated that by restoring Cx43 expression, the cell growth rate 
and neoplastic ability of the tumours could be decreased significantly.95Xia et al 
proposed that down-regulation of Cx43 expression was a common and a 
significant molecular event in carcinogenesis.68Given this fact, they hypothesize 
that Cx43 could be an important player in the early stage of development of 
OSCC. Cx43 expression in the fibroblasts of the connective tissue and its 
interaction with other cells could contribute additionally to fibrosis in OSF apart 
from exposure to arecanut alkaloids.90 
 The classical histopathological feature of OSF is considered to be 
deposition of collagen in the oral mucosa resulting from exposure to the areca-nut 
alkaloids.Tilakaratne et alstated that the fibrotic process in OSF is due to 
excessive collagen deposition and the disequilibrium in the extracellular matrix 
remodelling processes.96 There are studies stating that there is a significant 
increase in the incidence of epithelial dysplasia, as the thickness of fibrosis 
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increased and advancement of fibrosis increases the risk of development of 
epithelial dysplasia in OSF. 
 Thus, the oral mucosal connective tissue changes in OSF influence the 
malignant transformation of the epithelium and its progression and metastasis. 
Thus, both the epithelial and connective tissue alterations work in a coordinated 
matter to result in epithelial-mesenchymal transition.79 
` Pistorio et al studied the modulatory effects of Cx43 expression on GJIC 
with mast cells and fibroblasts. They used an in-vitro model which comprised of 
rodent derived peritoneal mast cell line (RMC-1 cells) and human dermal derived 
fibroblast. From their study, they stated that Cx43 is involved in promoting 
profibrotic fibroblast activities which can be modulated or regulated and can be 
considered as a potential therapeutic target in preventing excessive fibrosis.90 
 The limitations of this study are the small sample size and inability to 
distinguish the cell membrane and cytoplasmic staining to conclude that the 
downregulation of Cx43 could be an early event during oral carcinogenesis which 
could be considered as a biomarker for early changes in the malignant 
transformation of OSF. The observations of this study needs further research with 
a larger sample size.  
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 In this study, we had a total of 39 patients who comprised of 6 cases of 
group I (normal mucosa), 14 cases of group II (OSF), 12 cases of group III 
(epithelial dysplasia) and 7 cases of group IV (OSCC with history of 
OSF). 
 Age distribution in group II (OSF) was 50% of the cases were within 25-
50 years and 50% >50 years of age, whereas in group III (epithelial 
dysplasia) 50% of the cases were 25-50 years and 50% who were > 50 
years of age. The distribution of age between the groups was found to be 
statistically significant.  
 The study group II (OSF), group III (epithelial dysplasia) and group IV 
(OSCC with OSF) predominantly involved males. In group II (OSF), 71% 
were males and 29% were females. While in group III (epithelial 
dysplasia), 91% were males and 8% were females. In group IV (OSCC 
with OSF), 86% were males and 14% were females.  
 In group II (OSF), 64% had the habit of areca nut chewing and 35% had 
the habit of chewing areca nut and tobacco. In group III (epithelial 
dysplasia), 58% had the habit of chewing tobacco, 8% had the habit of 
chewing areca nut and tobacco and 33.3% were smokers. In group IV 
(OSCC with OSF), 57% had the habit of smoking and areca nut chewing 
and 29% had the habit of smoking and tobacco and areca nut chewing. 
 All the cases of group II (OSF) and group III (epithelial dysplasia) were 
taken from the buccal mucosa. In group IV (OSCC with OSF), 43% cases 
were from buccal mucosa, 14% from alveolar mucosa, 14% from palate 
and 29% from lateral border of tongue. 
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 Membranous expression of Cx43 was present in basal, suprabasal layers of 
epithelium and connective tissue. 93% of group II (OSF), 66% of group 
III(epithelial dysplasia) and 86% of group IV (OSCC with OSF) showed 
overall expression of Cx43.  
 In the basal layer, group II (OSF), there was no expression of Cx43 in 
71% of cases with 21% of the cases showing mild intensity pattern. 7.1% 
of cases showed moderate intensity of staining. In group IV (OSCC with 
OSF), all the cases did not express Cx43.  
 In group I, group III and group IV, Cx43 was not expressed in the basal 
layer. 
 There was a significant difference in the staining intensity of Cx43 in the 
suprabasal layer among the study groups.In Group II (OSF),50% of cases 
and 36% of cases showed mild and moderate intensity, respectively. 71% 
of cases in group IV (OSCC with OSF) did not express Cx43, 14.3 % of 
cases showed mild intensity and intense staining was seen in 14% of cases. 
In group III (epithelial dysplasia), 41.7% cases showed no expression, 
33.3% cases showed mild intensity pattern and 25% cases showed 
moderate intensity. 
 In Group IV, Cx43 expression was seen in two cases (28.6%) in the 
surface epithelium and the infiltrating epithelial islands in the connective 
tissue. 
 On comparing the Cx43 staining intensity of connective tissue, in group II 
(OSF) 7% did not express Cx43, 36% had mild expression, 50% had 
moderate expression and 7% with intense expression. In group IV (OSCC 
with OSF), 71% showed mild intensity of staining, 14% cases showed 
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moderate intensity and 14% showed intense staining.In group III 
(epithelial dysplasia), 33% showed no expression, 42% cases showed mild 
intensity and 25% cases showed moderate intensity. 
Cx43 was expressed in all the groups but its expression in the epithelium 
was not seen in four cases of OSF with dysplastic epithelium. Intense expression 
of Cx43 in the connective tissue was seen in OSF and OSCC. There was a 
reduced expression of Cx43 in cases of OSCC with OSF when compared to OSF 
cases. We postulate that downregulation of Cx43 expression could be an early 
event in carcinogenesis. These observations need to be further studied. 
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ANNEXURE II 
DISSERTATION PROTOCOL 
 
Title:  Expression of Connexin 43 (Cx43) in oral submucous fibrosis and in its malignant 
transformation 
Name and designation of the principal investigator:- 
Dr. R.N.Mugundan, 
I year post graduate student 
Department of Oral and Maxillofacial Pathology 
Name of HOD & staff in charge:- 
Dr .K .Ranganathan, MDS, MS (Ohio), PhD 
Dr .K .Umadevi, MDS 
Dr . Elizabeth Joshua, MDS 
Dr .T .Rooban, MDS 
Department where project is to be carried out:- 
Department of Oral and Maxillofacial Pathology, 
Ragas Dental College, 
Chennai 
Duration of the project:I year 
Background :- 
Head and neck cancers are the 11th most common malignancy worldwide. Oral 
squamous cell carcinoma (OSCC) can occur in various parts of the oral cavity like 
the buccal mucosa, gingiva, tongue and the palate. The tumor has a high mortality 
as a result of its high invasiveness and metastatic capacity. The OSCCs are 
usually preceded by premalignant lesions which are now referred to as Oral 
Potentially Malignant Disorders (OPMD) by World Health Organization (WHO). 
Since not all of the OPMDs progressed to malignancy. .Features of epithelial 
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dysplasia are seen in advanced OSF and could lead to their malignant 
transformation. Cellular cohesion is maintained by Gap junctions that connects 
the cytoplasm of one adjacent cell to the other, Connexins are gap junction 
proteins that are expressed throughput the epithelium. Among them Connexin 43 
(Cx43) is seen expressed extensively thoughout the tissues. Various studies have 
described the reduced expression of Cx43 in premalignant lesions and in 
carcinomas. There are no studies in the literature that had analyzed the Cx43 in 
oral submucous fibrosis and in its malignant transformation to oral squamous cell 
carcinoma 
Hypothesis:- 
There is no difference in the expression of Cx43 among OSF, Epithelial dysplasia 
and cases where OSF had undergone malignant transformation. 
Aim:- 
To evaluate the expression of Connexin 43 (Cx43), in formalin fixed paraffin 
embedded tissues of oral submucous fibrosis, epithelial dysplasia and OSF that 
had undergone malignant transformation to oral squamous cell carcinoma 
Objectives:- 
 To study the expression of Cx43in formalin fixed paraffin embedded  
tissues of Oral submucous fibrosis byIHC 
 To study the expression of Cx43in formalin fixed paraffin embedded  
tissues of epithelial dysplasia by IHC 
 To study the expression of Cx43 in in formalin fixed paraffin embedded 
tissues of OSF with OSCC byIHC. 
 To study the expression of Cx43 in formalin fixed paraffin embedded  
normal epithelial tissue by IHC 
 To compare the expression of Cx43 among the study groups 
Materials and Methods:- 
Study groups:- 
 Group -   I:Normal oral mucosa obtained with the patients consent during 
third molar extraction(n=6) 
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 Group - II: Clinically and histopathologically diagnosed cases of oral 
submucous fibrosis (n=14) 
 Group- III: Clinically and Histopathologically diagnosed cases of 
Epithelial Dysplasia (n=12) 
 Group-IV: Clinically and histopathologically diagnosed cases of OSCC 
with the history of OSF (n=7) 
Selection criteria:- 
 Group I–Normal mucosa obtained during removal of impacted third molar 
in the outpatient department of Oral and Maxillofacial Surgery department. 
 
 Group II–The criteria for selection of OSF patients were difficulty in 
opening the mouth, burning sensation of the mouth, palpable vertical fibrous 
bands in the oral mucosa. Histopathological criteria for OSF cases were epithelial 
atrophy, increased deposition of collagen in the oral mucosa,reduced vascularity, 
reduced number of inflammatory cells, and sub-epithelial hyalinization. The OSF 
was histopathologically graded by criteria given by Sirsat
 
and Pindborg.
 
 Group III - Clinically and histopathologically confirmed cases of 
Epithelial dysplasia which were graded histologically as mild, moderate and 
severe 
 Group IV- Clinically and histopathologically confirmed cases of OSCC 
with a history of OSF. 
Institutional review board:- 
This study was approved by Institutional Review Board (IRB) of Ragas Dental 
College and Hospital, Chennai.(Annexure I) 
Study setting:- 
Department of Oral and maxillofacial pathology, Ragas Dental College and 
Hospital. 
Methodology:- 
 Archival tissue samples of oral submucous fibrosis, epithelial dysplasia 
and oral squamous cell carcinoma accessed from Department of Oral Pathology, 
Ragas Dental College and Hospital. 
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 Demographic and pertinent details such as patient’s age, gender, past 
medical and dental history, history of drugs and trauma were obtained from 
records for OSF cases, OSCC arising in OSF cases and normal cases.  
 In group I, incisional biopsy were taken when patients were undergoing 
minor surgery for extraction of impacted teeth for normal oral mucosa after 
obtaining patient consent.  
 The tissue biopsied were rinsed and immediately transferred to 10% 
buffered formalin. 
 After adequate fixation, tissues were embedded in paraffin. 
 From the paraffin embedded blocks 5 micron thick sections were cut and 
used for routine hematoxylin and eosin (H&E) staining and immunohistochemical 
(IHC) staining. 
 Positive control for Cx43 was goat heart tissue sections. 
Immunohistochemistry was performed by:- 
Antibodies used:- 
Primary antibody –Anti-Cx43 rabbit monoclonal antibody, Dilution: 1:100 CAT 
NO- 71-0700 (ThermoFisherScientific
TM
) 
Secondary antibody-Poly Excel-HRP Micro polymer IHCDetection system, 
Pierce IHC Detection Kit, CAT NO- 36000(ThermoFisherScientific
TM
) 
Procedure:- 
The slides were dewaxed in xylene and rehydrated through grades of alcohol to 
water. The sections on the slides were flooded with Harris’s hematoxylin for 5 
minutes. The slides were washed in running tap water for 5 minutes. The slides 
were differentiated in 1% acid alcohol for 5 minutes. The slides were washed well 
in running tap water for 5 minutes. The tissue sections on the slides were then 
stained in eosin for 30 seconds. The slides were washed in running tap water for 1 
minute. The slides were then dehydrated through alcohol, cleared, mounted and 
viewed under light microscope. 
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Evaluation of H&E sections:- 
 The H&E stained sections were thoroughly examined. Oral squamous cell 
carcinomas were graded as well differentiated, moderately differentiated and 
poorly differentiated
.
 
 Epithelial dysplasia were graded as mild, moderate and severe. 
 Oral submucous fibrosis was graded histologically by criteria given by 
Sirsat and Pindborg. 
 Corresponding sections as examined by H & E were stained by IHC to 
detect Cx43 expression. 
 The positive control was a section of goat heart tissue that was previously 
shown to be positive for Cx43. 
 Cx43 expression was evaluated as brown membranous staining in the 
epithelial cells. 
 The cells were then assessed for staining intensity. 
Intensity of staining:- 
The staining intensity was analysed in the study groups. Each case was graded as 
(-) nil or absence of stain, (+) mild, (++) moderate and (+++) intensively stained 
based on the intensity of staining taken up by the tissue as observed by two 
blinded observers independently with respect to positive control. 
Tissue localization:- 
Epithelial cells that exhibited brown membranous staining were counted as 
positive for expression of Cx43. The sections were initially scanned at low power. 
For sections that showed heterogeneous staining, the predominant pattern was 
taken into account for scoring.  
Cellular localization of stain:- 
Brown Cx43 staining was seen as cytoplasmic or membranous granules. The 
stained slides were screened, examined systematically for Cx43 expression in 
cytoplasmic portion and walls of the epithelial cell. 
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Statistical test used:  The staining intensity between each groups was evaluated 
using Chi-squared test.Data analysis to be done using SPSS software (Statistical 
Package of Social Science) version 21. 
Signature of principal investigator 
Signature of Head of Department 
Remarks of committee 
Permission Granted YES / NO 
Modifications / comments 
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ANNEXURE III 
CASE SHEET 
 
 
 
Ragas Dental College & Hospital –Chennai 
 
Date of Diagnosis:   
 
Type of Biopsy: 
 
Name        :      Age :  Gender: 
 
Marital Status :     Occupation :  
 
Religion             :     Education: 
 
Dietary Habits  :  Vegetarian/Mixed/Non-Vegetarian 
 
Spice              :   Spicy/Moderate/Non Spicy 
 
CHEWING HABIT : (Swallowing/spitting/Pouching - R/L side) 
 Meth
od 
Frequency/
Day 
Quantity/
Day 
Duration 
Month/Ye
ar 
     
SMOKING HABIT : 
 
TYPE Number of Days Duration- 
Months/Year 
Ex Smoker 
Duration 
Cigarette with filter 
without 
filter/beedi/pipe/others 
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Any other Significant History Of alcohol and Drug abuse : 
 
Medical And Family History : 
 
Dental History : 
 
Presenting lesion : 
 
        Mouth Opening :  
        Tongue Protrusion : 
 
Cheek Flexibility : 
SITE OF THE LESION:    
1 .Gingiva LEFT RIGHT 
2.BuccalMucosa   
3 . Labial Mucosa   
4 . Vestibule –Buccal   
5.Tongue - Dorsal Surface 
                 - Ventral surface 
  
8. Palate - Hard Palate 
- Soft palate 
  
-    
9. Uvula   
10. Floor of the mouth   
11.Tonsillar area   
12. Oropharynx   
 
Description of Lesion : 
 
Provisional Diagnosis :’ 
 
Histopathological Diagnosis: 
 
 Annexures  
  
83 
 
ORAL 
SUBMUCOUS 
FIBROSIS 
STAGE 
STAGE – 1  
STAGE - 2  
STAGE – 3  
STAGE - 4  
 
 
MILD DYSPLASIA MODERATE  
DYSPLASIA 
SEVERE DYSPLASIA 
   
   
 
 
 
WELL DIFFRENTIATED 
OSCC 
MODERATELY 
DIFFRENTIATED OSCC 
POORLY 
DIFFRENTIATED 
OSCC 
   
   
 
Treatment Done: 
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ANNEXURE IV 
Connexin 43 – Cx43 Antibody FACT SHEET 
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ANNEXURE – V 
PLAGIARISM REPORT 
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ANNEXURE VI 
DEPARTMENT DECLARATION FORM 
 
The study title “Expression of Connexin 43 (Cx43) in oral submucous 
fibrosis and in its malignant transformation” have been done under the guidance 
of the staffs of the Department of Oral Pathology and Microbiology during my 
post - graduation during 2016 - 2019. The same has been submitted as a part of 
the syllabus MDS degree programme in Oral Pathology and Microbiology of the 
Tamil Nadu Dr. M .G.R . Medical University, Chennai. 
I shall publish in full or part of this work in any media with only with 
the prior written approval of the head of the department. 
 
 
 
 
 
 
R.N. Mugundan 
Post-graduate student 2016-2019 
Department of Oral and Maxillofacial Pathology 
Ragas Dental College and Hospital, Chennai 
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ANNEXURE VII 
ABBREVIATIONS 
 
 
 
 
1. OSCC - Oral Squamous Cell Carcinoma 
2. OPMD - Oral Potentially Malignant Disorder 
3. WHO - World Health Organization 
4. OSF - Oral Submucous Fibrosis 
5. IARC - 
International Association of Research on 
Cancer 
6. TGF-β - Transforming Growth Factor –β 
7. NF-κB - Nuclear Factor – kappa B 
8. IL-6 - Interleukin 6 
9. PG-E2 -      Prostaglandin E2 
10. GJIC - Gap Junctional Intercellular Communication 
11. GJ - Gap Junctions 
12. Cx43 - Connexin 43 
13. IHC  Immunohistochemistry 
14. H&E  Hematoxylin& Eosin 
15. PBS  Phosphate Buffered Saline 
16. HRP  Horse Radish Peroxidase 
17. DAB  Diamino benzene 
18. DPX  Dibutylphthalate Polystyrene Xylene 
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19. CTGF - Connective Tissue Growth Factor 
20. MMP - Matrix Metalloproteinases 
21. TIMP - Tissue Inhibitors of Matrix 
Metalloproteinases 
22. TNF- α - Tumor Necrosis Factor α 
 
23. VEGF - Vascular Endothelial Growth Factor 
24. IFN- γ - Interferon  γ 
25. IL-1 - Interleukin – 1 
26. FGF - Fibroblast Growth Factor 
27. PBMC - Peripheral Blood Mononuclear cells 
28. COX-2 - CycloOxygenase 2 
29. TGF-β1 - Transforming Growth Factor –β1 
30. TGF-β2 - Transforming Growth Factor –β2 
31. αVβ6 - Alpha V beta-6 Integrin 
32. ECM - Extra cellular Matrix 
33. SASP - Senescent Associated Secretory Phenotype 
34. MVD - Mean Vascular Diameter 
35. CK - Cytokeratin 
36. HMWCK - High Molecular Weight Cytokeratin 
37. PAN-CK - Pan Cytokeratin 
38. SNP - Single Nucleotide Polymorphism 
39. LOH - Loss Of Heterozygosity 
40. EMT  Epithelial Mesenchymal Transition 
41. ZO-1  ZonulaOccludens– 1 
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42. αSMA  Alpha Smooth Muscle Actin 
43. FSP-1  Fibroblast Specific Protein – 1 
44. kD  Kilo Dalton 
45. rER  Rough Endoplasmic Reticulum 
46. CDK  Cyclin Dependent Kinase 
47. CIP  Cyclin Inhibitory Proteases 
48. CSG  Chronic Superficial Gastritis 
49. Cx32 - Connexin 32 
50. HP - Helicobacter Pylori 
51. SIL  Squamous Intraepithelial Neoplasia 
52. HSIL - 
High Grade Squamous Intraepithelial 
Neoplasia 
53. 4NQO - 4-Nitroquinolone-1-Oxide 
54.  RMC-1  Rodent derived peritoneal Mast Cell – 1 
 
